Rank,OrgStudyId,WhyStopped,EnrollmentCount,PrimaryOutcomeMeasure,FlowDropWithdrawType
1,BTX-BCI-016-PRT,,3000,"To determine BCI test performance by evaluating the long-term outcome of BCI risk groups over the follow-up period., To determine medication adherence in patients undergoing extended endocrine therapy.",
2,2018-TJ-BCD,,2300,Diagnostic potential of SEMA4C as a biomarker for breast cancer,
3,Breast cancer,,80,Role of SORCIN in patients with breast cancer,
4,BC-BOMET,,30,SENP1 expression,
5,241391,,600,Performance of the Syantra DX Breast Cancer test as assessed by sensitivity and specificity,
6,IL-TM-B1-01,,200,"This study is intended to evaluate the sensitivity and specificity of the TM-B1 test compared to the Gold Standard diagnostic methods and clinical evaluations based on Digital X-Ray Mammography (XRM), and / or ultrasound, and / or MRI and / or pathology.",
7,FH-Risk 2.0 Research Protocol,,271,"To explore how much new risk models change breast cancer risk estimates, To compare breast cancer risk models, ""To explore womens risk appraises and experiences of receiving a revised breast cancer risk estimate",
8,ID-RPSBC-01-20201012,,316,"Absolute risk difference between breast cancer patients and non-breast cancer patients in terms of their non-genetic risk, Absolute risk difference between breast cancer patients and non-breast cancer patients in terms of their genetic risk",
9,IRST174.22,,60000,To compare the cumulative incidence of stage 2 or higher breast cancer between different screening intervals,
10,ANILERGÄ°NN,,300,breast cancer incidence after laparoscopic sleeve gastrectomy,
11,32155120.7.0000.0072,,105,Change in Global Health Status by EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire),
12,GCO 17-2188,,168,"Mammogram intention, Mammogram location and appointment",
13,233756,,15,To evaluate the efficacy of the HIFU treatment in achieving cancer ablation,
14,D16196,,18,The proportion of patients who had the localization wire placed within the cancer on the specimen mammogram,
15,LNs Staging of Breast cancer,,50,Diagnostic accuracy of preoperative ultrasound-guided axillary lymph node biopsy for staging in patients with newly diagnosed breast cancer.,
16,UMCC 2021.087,,40,"Acceptability of Intervention (AIM) Survey, Intervention Appropriateness Measure (IAM), Engagement with the patient decision aid",
17,RO1912-30902,,166,"Chest wall pain, Dysphagia, Skin, Pulmonary Toxicity, Brachial plexopathy, Lymphedema",
18,SA18i0002,,3269,Informed choice for breast cancer screening,
19,494936,,80,Assessment of breast cancer risk by polygenetic risk score in the study population,
20,042210,,16,"Measure glycolysis metabolism dependencies of hormone receptor positive/HER2 negative breast cancer using Liquid chromatography-mass spectrometry (LC-MS), Measure glycolysis metabolism dependencies of hormone receptor positive/HER2 negative breast cancer using Nuclear Magnetic Resonance (NMR) spectroscopy in parts per million (ppm).",
21,Yuan Shifang-1,,120,The level of CTC markers in breast cancer patients peripheral blood,
22,(818)109A-57,,70,"Change from the baseline score of the Symptom-Management Self-Efficacy Scale-Breast Cancer, SMSES-BC at the third chemotherapy (T1) and the sixth chemotherapy (T2)., Change from the baseline score of the Social Support Scale at the third chemotherapy (T1) and the sixth chemotherapy (T2)., Change from the baseline score of the Functional Assessment of Cancer Therapy - Breast, FACT-B at the third chemotherapy (T1) and the sixth chemotherapy (T2).",
23,21 SEIN 01,,61,Rate of patients with cancer cell / macrophage hybrid cells in peripheral blood defined as the ratio of the number of patients with hybrid cells to the total number of patients.,
24,18-181,,100,Precision and reliability,
25,catheter guided chemo-infusion,,50,Lesion size after chemotherapy,
26,2020/132,,150,"Health Belief Model Scale, Mammography Self-efficacy scale, Champion Breast Cancer Fear Scale, Motivational interview",
27,17-689,,82,Diagnostic accuracy of CESM compared with breast MRI for breast cancer screening,
28,831804,,30,Kinetics and Biodistribution of [18F]F-GLN,
29,PI-2842,,66,Dietary habits of a group of women with pre and post-surgical breast cancer,
30,260281,,65,Image quality of 23Na-MRI in the breast evaluated radiologically after each 23Na-MRI scan in healthy volunteers and patients.,
31,NCC2985,,1000,"Clinical features and trend, Diagnosis and treatment and trend, Survival situation and change trend",
32,Amr Ahmed,,200,"invasive Disease Free Survival at 3 Years from the time of randomization until the occurrence of the first of the following events: invasive local/regional recurrence, Contralateral invasive breast cancer, Distant recurrence, Death from any cause",
33,154/2019,Pandemic situation,36,"Pressure pain threshold over the shoulder of breast cancer patients after a physical therapy rehabilitation program following the surgery., Pressure pain threshold over the shoulder of breast cancer patients after a physical therapy rehabilitation program following the surgery., Strength grip of breast cancer patients after a physical therapy rehabilitation program following the surgery., Strength grip of breast cancer patients after a physical therapy rehabilitation program following the surgery.",
34,V1 11.12. 2020 (C.I.R.E.C.),,500,miRNA levels in plasma,
35,CLM-INS-004,,226,Prevalence of insomnia in a cohort of breast cancer patients,
36,miRNA in breast cancer,,50,Assess serum miRNA-373 and miRNA-425-5p expression in patients with breast cancer.,
37,2022-11-076-002,,1464,Cancer detection rate (CDR),
38,Health Literacy of Breast Ca,,60,"Information Form, Health Literacy Scale, Health Literacy Scale, Health Literacy Scale, Breast Cancer Screening Beliefs Scale, Breast Cancer Screening Beliefs Scale, Breast Cancer Screening Beliefs Scale",
39,MC1933,,100,Generate patient derived xenografts (PDX) and organoids from breast cancer patients with residual disease after neoadjuvant therapy,
40,RADIOVAL,,5000,Percentage of patients non-respondents vs respondents in neoadjuvant breast cancer treatment (Estimate tumor aggressiveness),
41,CE21096B,,300,the rehabilitation time,
42,ZY(2018-2020)-CCCX-2005-04,,200,"Disease free survival, Difference in quality of life scores as assessed by EORTC QLQ-C30, Difference in quality of life scores as assessed by EORTC QLQ-BR23",
43,MicroRNA in breast cancer,,50,"assessment of the value of MiRNA in diagnosis and prognosis of breast cancer patients, correlat MiRNA expression with MRI findings for better selection of treatment plan and out come",
44,GEICAM/2016-04,,850,"General condition: Age, General condition: performance status at diagnosis, General condition and history: substance abuse, Diagnosis of other primary tumors, Body mass index (BMI), Primary comorbidities, Mutational status of BReast CAncer gene (BRCA) or other genes of genetic predisposition, Family history of cancer, Anatomopathological characteristics of the tumor: date of diagnosis, Anatomopathological characteristics of the tumor: histology, Anatomopathological characteristics of the tumor: clinical and/or pathological stage, Anatomopathological characteristics of the tumor: hormone-receptor expression, Anatomopathological characteristics of the tumor: Human Epidermal Growth Factor Receptor 2 (HER-2) expression, Anatomopathological characteristics of the tumor: histologic grade, Anatomopathological characteristics of the tumor: Ki-67, Anatomopathological characteristics of the tumor: lymphovascular invasion, Treatment data: date of surgery, Treatment data: type of surgery, Treatment data: type of chemotherapy, Treatment data: adjuvant radiotherapy, Treatment data: adjuvant hormonotherapy, Treatment data: other type of anti-cancer treatment, Follow-up data: relapse type, Follow-up data: site of metastatic disease, Follow-up data: occurrence of other primary tumors, Follow-up data: current condition",
45,22IC7498,,34047,"Percentage uptake of breast cancer screening at three months- Intention to Treat, Percentage uptake of breast cancer screening at three months- Per Protocol",
46,BMIBC,,300,The percentage of obese breast cancer patients with response to treatment compared to non obese breast cancer patients.,
47,3.0840453,,135,Progression free survival,
48,HKG-KZ-BrCa-101,Technical problem with plasma blood samples obtained from the patients,165,DNA methylation of circulated tumor and PBMC DNA and its Correlation to Development and prediction of breast cancer,
49,Hibiscuss,,181,"Accuracy, Sensitivity, Specificity, Positive predictive value, Negative predictive value for breast cancer detection",
50,18 SEIN 11,,55,Rate of patients with successful mastectomy strategy by immediate reconstruction.,
51,SNAPS Breast Cancer,study did not start and is currently on pause,500,Primary Aim,
52,Pro00107118,,15,The proportion of patients with successful generation of PDMO from the patients biopsy,
53,ZCHBC022,,40,"Correlation between DCE-MRI parameters combined with IVIM parameters and short-term efficacy of chemotherapy in patients with liver metastasis of breast cancer, Correlation between DCE-MRI parameters combined with IVIM parameters and long-term efficacy of chemotherapy in patients with liver metastasis of breast cancer",
54,R.18.02.34.R1.R2,,650,Prevalence of HCV Seropositivity in Breast Cancer Patients.,incomplete data on file
55,17-447,Principal investigator left the study institution.,0,"PET-MRI Visualization and Quantification of Breast Tumor Uptake of [11C]Martinostat Above Background Uptake, as Assessed by SUV Measurements",
56,22-509,,15,"Recruitment Retention Rate, Time Required to Recruit to Target, Proportion of Eligible Participants, Rate of Intervention Completion, Success Rate of Educational Intervention, Data collection feasibility",
57,ID-BCRPS-02-20220913,,20,Focus Group Discussions,
58,17-01549,,170,To compare GSI-measured breast SFA fraction between women with malignant and benign lesions.,
59,112991,,15,"Detection of Imaging Biomarkers of acute cardiac inflammation, Detection of Imaging Biomarkers of late cardiac inflammation, Detection of Imaging Biomarkers of acute cardiac perfusion changes, Detection of Imaging Biomarkers of late cardiac perfusion changes, Detection of cardiac fibrosis",
60,202101073,,1277,"Change in Total Knowledge Score of Screening Mammography Guidelines, Feelings of Being Fully Informed and Clear About the Importance of the Components for Making Informed Decisions as Measured by the Decisional Conflict Scale (DCS), Values Clarity Subscale, Decision Self-efficacy as Measured by the 5-Point Decision Self-Efficacy Scale, Preparation for Decision Making Scale as Measured by PrepDM","Failed to meet screening criteria, Overquotas removed, Removed from study for not meeting protocol criteria for free responses to knowledge questions"
61,TET-21-001,,60,Number of commercial Antibodies capable of Identify specific Breast Cancer Biomarkers,
62,"estPerMed 1, Breast",,28389,Proportion of women in the population with genetically higher risk for breast cancer,
63,68824072019,,77,"Breast Cancer Screening, Health Belief Model Scale (Susceptibility, Health Motivation sub-factors), Breast Cancer Fear Scale, Healthy Lifestyle Behaviors Scale II (Health Responsibility, Physical Activity and Nutrition Sub-Scale), International Physical Activity Questionnaire (IPAQ)",
64,3055,,2780,Five year overall survival,
65,20220303swj0211,,90,To examine the efficacy of brief acceptance and commitment therapy on disease acceptance and quality of life of breast cancer patients,
66,RC20_0532,,66000,Participation in organised screening for breast cancer,
67,Breast Cancer Risk,,16164,Incident breast cancer within 3 months to 7 years after the assessment of sonographic GTC,
68,KMUHIRB-E(I)-20200041,,73,Self-efficacy,
69,VGHKS18-CT11-17,,351,Total number of cases received and diagnosed with breast cancer (Number),
70,832165,,50,PARP-1 Activity in Breast Cancer,
71,LCCC2207,,15,"Key barriers for use a metastatic breast cancer-specific prognostic tool, Key facilitators for use of a metastatic breast cancer-specific prognostic tool",
72,ICO-2019-08,,36,"Evaluate the quality of life of patients with an adjuvant breast cancer treated at the ICO depending on the patient benefit or not from the TM during the chemotherapy in a hospital day care, Change from basline quality of life during breast cancer treatment",
73,biomarkers in breast cancer,,80,measure chemerin and Circular RNA in breast cancer patients,
74,GEICAM/2017-07,,1000,"Number of participants with breast cancer diagnosis during the gestation, breastfeeding, first year after the delivery (not during breastfeeding period), after a pregnancy and followed by any fertility preservation method before the anticancer treatment, Race of participants with breast cancer diagnosis during the gestation, breastfeeding, first year after the delivery (not during breastfeeding period), after a pregnancy and followed by any fertility preservation method before the anticancer treatment, Age of participants with breast cancer diagnosis during the gestation, breastfeeding, first year after the delivery (not during breastfeeding period), after a pregnancy and followed by any fertility preservation method before the anticancer treatment",
75,MCC-21448,,100,"Rate of Brain Metastasis, Rate of Brain Metastasis",
76,4452,,367,Development of a HDI classifier enabling early noninvasive diagnosis of breast cancer with similar accuracy compared to breast biopsies,
77,UPCC 19121,,300,"Collecting, processing and archiving breast cancer tumor tissues",
78,autotaxin1,,110,Autotaxin as a tumor marker,
79,2017-0588,,11,Reach: Proportion of Participants who Utilize the Decision Aid,
80,SK-421-BRCA,,66,Cancer-specific Quality of Life,
81,DS8201-A-U302,,524,"Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane","Progressive Disease, Clinical Progression, Adverse Event, Withdrawal by Subject (from treatment only), Lack of Efficacy, Physician Decision, Miscellaneous"
82,LQ005,,100,"Pathway regulatory mechanism during palbociclib treatment on ER+/HER2- breast cancer., Patterns of clonal changing on lesions during treatment of palbociclib combined endocrinotherapy.",
83,21-480,,70,Identify barriers for breast cancer diagnosis in Tanzania.,
84,CCR 5113,,240,Goal achievement,
85,ICO-N-2017-02,The study was stopped prematurely due to insufficient recruitment,50,False-negative rate in patients with a second SLNB procedure for IBTR,
86,medicin,,100,To estimate the level of serum ATX as a diagnostic marker for breast cancer.,
87,METCZ20200211,,40,The concordance in detection of sentinel nodes by Magtrace and the Technetium tracer.,
88,2021LC2210,,30000,The performance of breast cancer screening based on AB US with remote reading mode,
89,2020-A00058-31,,1100,Validation of the value of molecular profiling analysis in broadband laser spectroscopy on liquid biopsies for breast cancer screening,
90,NCC3299,,1821,pathological complete response,
91,17-581,,17,Decision-making around endocrine therapy in young women with HR+ breast cancer.,
92,ESR-21-21505,,2500,"the treatment pattern in HER2+, and HR+HER2- early and advanced breast cancer patients in county in each cohort",
93,2014P002688a,,17379,"Cancer detection rate, Loss to follow-up, Patient volume and services received",
94,PekingUPH10B004,,46,pathological complete response(pCR),
95,351-19,,74,"Relative blood volume, Blood flow, Change of relative blood volume, Change of blood flow",
96,ODELIA,,25000,Diagnostic performance for breast cancer detection (Sensitivity and specificity),
97,LUMHS/REC/-17,,382,"Histopathology of tumour, Steroid receptor status",
98,CD3-MUC1 in breast cancer,No participants enrolled,0,Objective response rate,
99,LCCC 1829,,500,"Change of treatment plan based on physician survey, Overall rate of clinical:molecular primary tumor subtype incongruence",
100,2022-080,,30,pathologic complete response,
101,20218,,13,"Identification of a maximum tolerated dose combination (MTDC) of entinostat and capecitabine, Frequency of adverse events (AEs) in participants with high-risk breast cancer after neo-adjuvant therapy, Severity (as graded with the Common Terminology Criteria for Adverse Events (CTCAE)) of adverse events (AEs) in participants with high-risk breast cancer after neo-adjuvant therapy",
102,2017-03-002A,,120,Diagnostic performance of PET/MR imaging metrics in prediction of treatment response to chemotherapy,
103,2018-TJ-BCP,,4200,"diagnostic accuracy (sensitivity, specificity, positive predictive value, negative predictive value) of SEMA4C in predicting recurrence of breast cancer",
104,LA LEAST,,290,Distant Relapse Free Interval at five years,
105,2015-004027-31,,24,"Tumoral uptake of [18F]GE-226 in patients with breast cancer measured using semi-quantitative parameters, Tumoral uptake of [18F]GE-226 in patients with breast cancer measured using fully quantitative parameters",
106,1905795920,PI no longer working at Indiana University;,25,Fear of Cancer Progression and Recurrence (FCR7),
107,4-2018-0254,,200,The incidence rates of brain metastases with high risk patients in metastatic breast cancer,
108,495077,,300,Change in staging and/or management due to added 18F-FDG PET/CT scan,
109,CCR4684,,58,"Percentage of Breast Cancer Cohort Participants With Objective Response Assessed Using RECIST v1.1, Percentage of Basket Cohort Participants With Objective Response Assessed Using RECIST v1.1",
110,211753,,500,Proportion of eligible women who receive breast cancer risk assessment,
111,22-136,,60,Compare the rate of wound complications for partners who receive neoadjuvant radiotherapy (NART) and modified radical mastectomy with immediate autologous reconstruction (IR) following neoadjuvant chemotherapy (NAC) compared w/current standard of care,
112,BREACE,,100,Change in the 30-second chair stand test,
113,1705018188,Temporarily paused per study team for interim data review.,14,Specificity of the PET-MRI Compared to MRI Alone as Assessed by the Percentage of True Negatives Out of All Benign/Non-malignant Lesions Breast Cancer,
114,CDK-HeCOG-2019,,340,Toxicity rates,
115,RECO_CT29B,,200,"Detection (presence/absence) of specific urinary biomarker targets (HER2, PIK3CA) for breast cancer patients measured using ddPCR.",
116,2020-0327,,88,Radiological evaluation of response to neoadjuvant chemotheraphy for breast cancer,
117,D8531C00002,,4300,Invasive breast cancer-free survival (IBCFS),
118,SOLTI-1910,,28,"Capacity of the RAD51-foci score to predict the efficacy of olaparib in BRCA1/2, PALB2 or RAD51C/D mut advanced breast cancer (cohort 1)",
119,SH ABCD,,1550,Autoantibodies for breast cancer diagnosis,
120,1905202-3,,5000,The frequency of pathogenic or likely pathogenic variants of BRCA1/2 and other genetic susceptibility genes in Chinese community breast cancer population,
121,2022-8048-23560,,26,Occult breast cancer frequency,
122,Targeted axillary dissection,,30,"Evaluation the sensitivity of targeted axillary lymph node dissection in node positive breast cancer patients, Comparing sensetivity of targeted axillary dissection with traditional SLND",
123,2021-0215,,40,Change in tumor infiltrating lymphocytes (TILs) count in primary tumors from patients with high-risk early stage breast cancer following low-dose azacitidine therapy.,
124,2019-A01861-56,,90,"Assessment of the correlation between the lymphocyte infiltration rate assessed on biopsy, and the NLR (neutrophil-to-lymphocyte ratio) measured on blood samples, in women with triple negative breast cancer, at the time of diagnosis.",
125,GFY202001,,200,To evaluate the trend of anti-MÃ¼llerian hormone (AMH) level at chemotherapy process and post-chemotherapy in breast cancer patients.,
126,18-634,,250,"Adjuvant treatment recommendations, Adherence to hormonal therapy, Barriers to treatment and adherence, Treatment patterns by age and other characteristics",
127,IRB # 21-0026,,50,Number of participant tear samples collected.,
128,IRB00002991,,50,"Time spend on the online adaptive workflow, Patient experience, Dosimetric data, DICOM images, Volumes, Number of monitor units (MU).",
129,LCCC 1954,,39,Feedback from patients regarding healthy weight communication through focus groups,
130,20 KHCC 202,,1000,"Prevalence of pathogenic or likely pathogenic germline variants among newly diagnosed breast cancer patients tested by universal multigene panel testing or guideline-based targeted testing, Number of participants with variants of uncertain significance (VUS) as assessed by universal multigene panel testing versus guideline-based targeted testing, The reasons/ Barriers for refusal of genetic cascade testing among newly diagnosed cancer patients",
131,ESR-17-12934,,390,Diagnostic performance of PD-L1 expression in breast cancer,
132,69HCL22_0613,Study classified as out of scope by the Ethics Committee (not a project involving human person).,0,Change in Quality of life questionnaire score,
133,17-398,,45,"Recruitment rate, Attrition rate, Change in distress",
134,LCCC2213,,30,Determining the key patient and caregiver factors impacting implementation of a metastatic breast cancer prognostic tool through semi-structured qualitative interviews.,
135,IC 2018-01,,15,Ascertain breast cancer olfactive signature (Isolation of volatile Organic Compounds to breast cancer by a sensitive technique with an odor-sensing polymer (SorbstarÂ®),
136,IC 2020 08,,35,To ascertain the possibilities to isolate the breast cancer olfactive signature,
137,PI17/00834,,387,"Attitude towards personalised breast cancer screening (by participant women), Intention to participate in personalised breast cancer screening, Satisfaction with personalised screening",
138,FMASUMD232/2021,,40,Describe miRNA 21 expression level before and after neoadjuvant systemic therapy in breast cancer patient.,
139,PekingUMCH-FAPI-BC-2,,100,"The maximum standard uptake value (SUVmax ) was measured in the breast cancer lesions on Al18F-NOTA-FAPI-04 PET/CT., Standardized uptake value of Al18F-NOTA-FAPI-04 in BC",
140,PekingUMCH-FAPI-BC-1,,100,"SUVmax was measured in the breast cancer lesions on 68Ga-FAPI PET/CT., Standardized uptake value of 68Ga-FAPI in BC",
141,Breast immune checkpoint,,60,Immune checkpoints,
142,180034,,30,"Cohort 1 - Progression-free Survival (PFS), Cohort 2 - Overall Response Rate (ORR) (Complete Response (CR) + Partial Response (PR) by the Response Evaluation Criteria in Solid Tumors (RECIST), Cohort 3 - Overall Response Rate (ORR) (Complete Response (CR) + Partial Response (PR) by the Response Evaluation Criteria in Solid Tumors (RECIST)","Ineligible, Participant declined to participate before treatment started"
143,IRB17-0721,,74,Rate of overall response based on RECIST 1.1,
144,REO 027,Enrollment into AWARE cohorts1-4 have concluded and the primary objective and core goals for the study were met.,26,To evaluate if pelareorep in combination with different therapies increases the value of the CelTIL score in women with operable early breast cancer. CelTIL is a combined IHC-based score based on tumor cellularity and stromal TILs.,
145,CentroHLO_EFBreastCancer,,200,"Global medical assessment, Assessment of changes in the cardiac function/fitness status of the subjects",
146,BCL IDE,,448,Positive margin rate,
147,2018-177-IMP-EXP-4,,1000,"Correlation of TILs and PDL-1 in various molecular sub-types, PDL-1 expression in patients with Triple Negative Breast Cancer (TNBC), TILs and Tumor response to treatment, PD-L1 expression and Tumor response to treatment",
148,elastography in breast cancer,,35,shear wave elastography assessment in patients with invasive breast cancer.,
149,V3-MOMMO-01,,20,Effect on tumor size,
150,PROICM 2020-01 OST,,246,Evaluate the prevalence of pelvic static disorders in patients treated for localized breast cancer and undergoing adjuvant hormone therapy (Hormontherapy +).,
151,077-2019,,20,Incidence of toxicity and adverse events using MRg-FUS+MB treatment in patients with chest-wall and locally advanced breast cancer,
152,84434789,,500,"Number of triple negative breast cancer patients who decide to enroll in a clinical study, Rate of triple negative breast cancer patients who remain in a clinical study to completion",
153,CBS-PIK3CA,,120,"Clinical performance of PIK3CA kit in CTCs, plasma and tumor tissue samples of metastatic breast cancer patients",
154,JuÃ§ara Phd Thesis,,110,Post-treatment Satisfaction,
155,2021-004,,20,Investigate the acute effect of chemotherapy administration on protein turnover cellular processes through vastus lateralis biopsies of breast cancer patients,
156,18-281,,60,"The extent to which the Prosigna test results will change physicians pre-test decision regarding neoadjuvant treatment of patients with stage II-III ER/PR+, HER2-negative breast cancer",
157,2021-A02676-35,,163,Rate of establishment of exploitable organoids tumor,
158,ARNA Breast 2021,,500,Number of woman with positive ARNA Breast test confirmed by biopsy (Sensitivity),
159,18 SEIN 08,Slow recruitment rate,4,The rate of patients with conversion of FES negative lesions in FES positive lesions.,
160,SNP-17-001,,118,Change in Breast Cancer Risk Management Recommendations,
161,2021-012,,58,"Evaluation of DIBH and IMRT efficacy in preventing perfusion defect for left-sided breast cancer after radiotherapy, Evaluation of DIBH and IMRT efficacy in preventing perfusion defect for left-sided breast cancer after radiotherapy, Evaluation of DIBH and IMRT efficacy in preventing perfusion defect for left-sided breast cancer after radiotherapy",
162,2394,,1950,"Selection of features, Nomogram",
163,69HCL18_0769,,2264,Participation of HCL female staff in mammography screening for breast cancer,
164,2020-KY-064,,80,Progression Free Survivalï¼PFS,
165,CASE12119,,100,"Percent of participants who took up genetic testing after not meeting NCCN guidelines for genetic testing, Mean overall patient satisfaction with decision about genetic testing: survey, Overall comprehension as assessed by BCGCKQ",
166,18-124,,82,5-year invasive disease-free survival rate,
167,EFC16133,"Sponsor decision to prematurely stop the study, not linked to any safety concern",3,Invasive breast cancer-free survival (IBCFS),
168,964635,,212,"The number of participants with no more tumor in their body, PFS (progression free survival), Overall Survival (OS)",
169,3049,,537,Primary aim of this study is to identify patients perception of modesty during RT for breast cancer through the use of a dedicated 16 items questionnaire validated in a Delphi consensus for the purposes of this study,
170,18-461,,209,Patient-reported outcome questionnaire - Fertility Preservation Questionnaire,
171,82944089,,500,"Rate of patients who decide to enroll in a metastatic breast cancer clinical study., Number of metastatic breast cancer study participants who remain in clinical trial until completion.",
172,NewGiza University Protocol 1,,200,Confirmed Breast Cancer Patients,
173,s66248,,250,"Subjective upper limb function, Objective upper limb function, Prognostic value of presence of skin deformities, asymmetry, presence of scapular winging or other scapular or shoulder deformities, Prognostic value of pain intensity, Prognostic value of presence of neuropathic pain, Prognostic value of presence of sensory loss, Prognostic value of presence of widespread pain, Prognostic value of impact of pain on functioning, Prognostic value of Soft tissue stiffness index, Prognostic value of Total relative arm volume (%), Prognostic value of movement functions during a functional task, Prognostic value of Upper limb muscle strength (kg), Prognostic value of Pain catastrophizing, Prognostic value of Self-efficacy, Prognostic value of Depression, Anxiety and Stress, Prognostic value of Fear of movement, Prognostic value of Body-perception, Prognostic value of Quality of Life, Prognostic value of (Sub)optimal physical therapy care, Prognostic value of treatment with Chemotherapy, Prognostic value of treatment with Hormone therapy, Prognostic value of soft tissue adhesions",
174,2019402,,102,Breast cancer-related quality of life - total score,
175,Protocol EMIT-1,,2298,"Treatment decision differences with or without Prosigna test, Distant disease free survival",
176,19-003085,,900,Patient self-reported intention to take a breast cancer preventing medication,
177,SCCC-11118; STU-2018-0015,,61,Measure Ki67 index in highly hormone-dependent breast cancers vs. those that are not,
178,RADIO-SLEEP,,51,Number of Participants With Decreased Sleep Disorders,
179,3/19,,1000,"Multiparametric flow cytometry analyses of Custer of Differentiation (CD) proteins expression on tumor infiltrating lymphocytes, Analysis of gene expression profiles of cancer cells, Extraction of features from radiological images to be used as biomarkers., Bioinformatics analysis",
180,2017/1356,,1411,"Medication Possession Ratio (MPR) as a proxy for medication adherence, Survival",
181,17/09/621_Myosin VI,,120,"Gene expression of Myosin VI and oestrogen receptor targets in tumour tissue., Quantification of Myosin VI protein in tumour tissue., Localisation of Myosin VI on the tumour genome",
182,left breast cancer,,45,retrospective study of cardiac toxicity in left breast cancer received hypofractionated radiotherapy,
183,IC 2016-07,,1004,Spontaneous pregnancies between cases and controls,
184,180212-1,,168,In-Breast Tumor Recurrence (IBTR),
185,19-001,,45,Rate of Change in Intentions for Mammography in the Next Year,
186,UCaenNormandie,,91982,"Aggregated breast cancer screening participation rate 3 months after the last invitation, Individual breast cancer screening participation rate 3 months after the last invitation, Impact of the mobile unit on social inequalities in screening participation, Impact of the mobile unit on territorial inequalities in screening participation",
187,CTRP6 in Breast Cancer,,102,To investigate the CTRP6 levels in breast cancer.,
188,CESM in breast cancer,,50,Accuracy of contrast enhanced spectral mamography in the predicting of pathological response to NAC and assessment residual disease in breast cancer patients,
189,SOLTI-1903,,600,Metastatic breast cancer management based on tumor molecular profile,
190,Vitamin D in breast cancer,,222,Correlation of vitamin D levels with prognostic features,
191,17-552,,910,Diagnostic accuracy of breast restriction spectrum imaging (RSI) in comparison to conventional breast MRI,
192,STUDY00011606,,500,"Trust, Intention to Use",
193,CCR5348,,400,Incidence of patients with ctDNA detection treated with surgery for stage 1 breast cancer,
194,19HLSEIN02,,100,"Identify Change of immune ME by TILS quantification of triple-negative breast cancer induced by neoadjuvant chemotherapy for all patients, Identify Change of immune ME by PDL1 expression of triple-negative breast cancer induced by neoadjuvant chemotherapy for all patients, Identify Change of immune ME by TIM3 expression of triple-negative breast cancer induced by neoadjuvant chemotherapy for all patients, Identify Change of immune ME by LAG3 expression of triple-negative breast cancer induced by neoadjuvant chemotherapy for all patients",
195,200056,"One participant was accrued, and the study was stopped due to new safety data from the company for M7824 and slow accrual.",1,"Overall Response (Partial Response + Complete Response) for Participants With Triple Negative Breast Cancer (TNBC), Overall Response (Partial Response + Complete Response) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2) + Breast Cancer (BC), Number of Participants Experiencing at Least One Grade 3 to 5 Adverse Events for Each of the Three Combinations of Agents",Study closure by sponsor
196,03/21,,31,"Sensitivity and specificity of contrast-enhanced CT lymphography, Preoperative detection of sentinel lymph nodes metastases",
197,AHQU-2021007,,60,Difference of BFI score change after treatment,
198,D8530C00003,,132,Change from baseline in estrogen receptor (ER) expression between pre- and on-treatment tumour samples measured by immunohistochemistry (IHC),
199,2019-05-157,,300,Genomic profiling of MBC patients,
200,182-20-CA,,124,Detection of unsuspected distant metastases,
201,KY20192114-C-1,,21000,"the performance rate of sentinel lymph node biopsy (SLNB) in patients with early stage breast cancer in China, the positive rate of SLNs in patients with early stage breast cancer in China, the number of resected SLNs in patients with early stage breast cancer in China",
202,STUDY19060359,,1650,Cancer Detection,
203,2019.089,,400,area under the receiver operating characteristic curve (AUC),
204,NeoRadUKD,,1826,disease free survival (DFS):,
205,004181,,480,"Evaluate the changes in the quality of life of the breast cancer survivor across the pre to post to follow-up measurement time points., Evaluate the changes in the satisfaction of the relationship between couples who are married across the pre to post to follow-up measurement time points.",
206,Shengjing-LCG008,,450,Invasive Disease-Free Survival (IDFS),
207,Xist,,1,detection of X inactive specific transcript RNA deletion in patients with breast cancer,
208,HERMIONE 13,,150,Description of the choices for second line treatment in patients affected by advanced HR+/HER2- breast cancer who progressed after CDK4/6i in association with hormonal therapy.,
209,NL75855.091.21,,413,"Non-inferiority of CEBCT error rate vs DCE MRI error rate, both as compared to the golden standard for tumor staging., Non-inferiority of CEBCT to predict pCR after primary systemic therapy as compared to DCE MRI.",
210,CASE5118,,50,"Microbiome profile as assessed by stool sample, Microbiome profile as assessed by breast skin sample, Correlation of the microbiome to incidence of at least grade 3 skin toxicity using the CTCAE version 4.0 scoring",
211,UEM0002,The researcher who was able to recruit the patients abandoned the project.,0,Change in Quality of life of breast cancer survivors,
212,21 SEIN 09,,120,"Main study: the primary endpoint is the Area under the Receiver Operating Characteristic Curve (ROC Curve) of POLQ expression to identify patients presenting progressive disease or death at 6 months under PARPi alone (primary resistance)., Sub-study: the primary end point is the rate of patients presenting loss of Shieldin complex and/or 53BP1.",
213,CINEICC-3-IAT,,154,"Change from baseline Cancer-specific quality of life, functioning, and symptoms at 6 months (The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; Fayers, Aaronson, & Bjordal, 2001), Change from baseline Depressive symptoms and anxiety severity at 6 months (Hospital Anxiety and Depression Scale - HADS; Zigmond & Snaith, 1983).",
214,Bakircay University,,64,"Functional Assessment for the Cancer Treatment - Endocrine Symptoms Quality of Life Scale (FACT-ES QLS), National Comprehensive Cancer Network (NCCN) Distress Thermometer",
215,STANDPOINT,,50,Verify the subtype value of dual-PET in extrahepatic metastases,
216,21149002,,66,"State Anxiety Scale, Cancer Fatigue Scale",
217,21-528,,670,"COVID-19 Vaccination on Contralateral Arm, Lymph Node Swelling after mRNA COVID-19 Vaccine",
218,HR-HER2-RWS-01,,200,Total pathological complete response (tpCR),
219,AAAU1629,,55,Patient Activation,
220,DS8201-0002-EAP-MA,,200,Real-World Time-to-Treatment Discontinuation In Participants Treated With Trastuzumab Deruxtecan (T-DXd),
221,2020-12/898,,91,Metabolomic profiling of ESP block for breast cancer surgery,
222,01-BR-003,,109,"Overall Survival, Progression Events, Subject Lost-to-Follow-Up",
223,PI-0538-2017,,150,"Metagenomic study of mammary microbiota, Metagenomic study of intestinal microbiota",
224,2020[84],,40,"Visual Assessment of HER2 expression in Breast cancer using 99mTc-NM-02 SPECT/CT Scan, Semiquantitative Assessment of Breast and other Metastatic Lesions in 99mTc-NM-02 SPECT/CT Scan, Safety of 99mTc-NM-02 through Adverse Event Monitoring, Safety of 188Re-NM-02 through Adverse Event Monitoring",
225,IRB202100182 -N,,68,"Change in brachial artery FMD, Change in global longitudinal strain, Feasibility, tolerability and safety of exercise training during breast cancer chemotherapy",
226,BC-NEO-IIT-SHR1316-SHR6390-RT,,24,"Pathological complete response (pCR) for TNBC group, Residual cancer burden (RCB) 0-I index for HER2-/HR+BC group",
227,121K686,,51,"Change in Post-traumatic Growth Inventory, Change in Event-Related Rumination Inventory (ERRI), PTSD Checklist for DSM-5 (PCL-5)",
228,CHIR-07-Sentimag,,70,"Accuracy of Magseed placement, Surgeon-rated ease of detected lymph node localization and removal, Number of nodes retrieved within the surgical specimen containing the Magseed, Surgeon-rated ease of detected labeled lesion localization and removal, Transcutaneous detection rate, Incidence of adverse events",
229,2019-KY-001-003,,15,"Number of participants with adverse events and dose limiting toxicities as assessed by CTCAE v5.0, Incidence of treatment-emergent adverse events [safety and tolerability] of dose of PD-1 Knockout CAR-T cells will be assessed using CTCAE v5.0, Monitoring the numbers of circulating AJMUC1 after infusion will be evaluated.",
230,06-2020,,162,"Prevalence of Depression Symptoms, Prevalence of Anxiety Symptoms",
231,CHUBX 2016/19,,35,Feasability of the web portal,
232,AbantIBU,Unable to achieve device(s) which will be used in this study.,0,Investigation of early detection of lymphedema after breast cancer surgery with Bio Electrical Impedance Analysis (BIA),
233,Breast Cancer,,60,"Distance Incremental Shuttle Walk Test (SWTI), Maximum endurance test (1RM)",
234,21/4657,,100,"Results of the Readiness and Enablement Index for Health Technology (READHY), Grouping using (Readiness and Enablement Index for Health Technology) READHY-scores",
235,URomLS Prot.0930/2021Rif. 6528,,20,"Immunogenic Cell Death induced by tumor cryoablation, cytokines, Immunogenic Cell Death induced by tumor cryoablation, pro-inflammatory cytokines, Immunogenic Cell Death induced by tumor cryoablation, immunosuppressive cytokines, Immunogenic Cell Death induced by tumor cryoablation, chemokines, Immunogenic Cell Death induced by tumor cryoablation, ATP and HMGB1",
236,BSU,,80,Clinical benefit rate (Tumor size),
237,NADOPTIC,,20,"Optical monitoring of neoadjuvant chemotherapy in breast cancer patients, Prediction of pathological complete response to neoadjuvant chemotherapy using optical imaging",
238,2020-0724,,1200,"Sensitivity of the Droplet-BC screening test for detecting breast cancer, Specificity of the Droplet-BC screening test for detecting breast cancer",
239,17-PP-19,,320,Number of women who had pre- and per-gravidic exposure and who developped a breast cancer,
240,Pro00020917,,39,Pathological complete response (pCR) rate in the breast in patients with HER2-enriched and HER2-amplified breast cancer,
241,LCCC 1749,,100,Compare the change in p16 from baseline to end of chemotherapy,
242,22-x145,,256,"Safety Lead-In: Number of treatment-related complications, Randomized Controlled Trial: Ipsilateral breast cancer recurrence (IBTR) in the treated breast.",
243,SOLTI-1716,,46,Overall Response rate of pembrolizumab in combination with paclitaxel in HR+/HER2- non-luminal subtype advanced breast cancer defined by the PAM50 assay,
244,2015-4-6-003,,144,Impact of Learning workshops (self massages and self stretching) on sequelae pain after breast cancer surgery,
245,GIMI-IRB-20005,,100,Number of patients with adverse events.,
246,147/19,,224,"Feasibility of an Educational Intervention: Adherence to the Intervention, Feasibility of an Educational Intervention: Drop Out After the Intervention Period, Number of Diet and Activity Recommendations, Breast Cancer Awareness",
247,STUDY00001641,,320,Screening adherence,
248,MD 177/2021,,80,"Variation of PD-L1 expression in Her-2 positive and triple negative breast cancer, Correlation between pathological complete response and PD-L1 expression",
249,PetrovRIO,,60,False negative rate of vacuum-assisted biopsy (FNR),
250,FIRST,,30,Tumor ablation,
251,19-001004,,120,"Brain activity comparison between breast cancer survivors undergoing endocrine therapy and healthy matched control subject., Cognitive function comparison between breast cancer survivors undergoing endocrine therapy and healthy matched control subject.",
252,A5481177,,500,Number of Participants With HR+ HER2- Advanced Breast Cancer (ABC) Treatment Patterns,
253,PUMCH-BREAST-ctDNA screening,,300,ctDNA test model for early screening of breast cancer,
254,2017-KY-19,,288,"overall survivalï¼OS, Tumor specific survival time, CSS",
255,19049,,50,"Proportion of specialist service that recommends chemoprevention prescribing by areas in England, Chemoprevention medication prescribing rates in primary care by area in England",
256,Z211100002921033,,175,"pCR(complete pathological response), Objective response rate (ORR), Quantification of CIC structure in tumor tissue",
257,Radiotherapy in breast cancer,,47,Disease free survival,
258,Breast cancer neoadjuvant,,45,Immune checkpoints,
259,CFDAIIUASABFDOBC,,116,"Diagnostic values of cell free DNA using ALU (Arthrobacter luteus) sequence levels (247 bp (base pair), 115bp) and its integrity in peripheral blood of breast cancer patients as non invasive marker.",
260,SYSEC-KY-2018-018,,358,Overall survival,
261,852-20,Study is moving to a different institution with PI.,0,"Change in inhibitory control, Change in cognitive flexibility, Change in executive function processing, Change in spatial working memory reaction time, Change in short-term memory, Change in verbal memory, Change in relational memory, Change in spatial working memory accuracy, Change in brain volume, Change in white matter integrity, Change in resting state functional connectivity, Change in self-reported cognitive function",
262,2020-KY-063,,200,Correlation between biomarkers and efficacy of tumor therapy,
263,PROICM 2019-16-BCU,,45,Sexual quality of life: EORTC SHQ-C22 questionnaire,
264,wanghaibo,,10,Adverse Events (AE),
265,IBCSG 59-19,,400,Duration of invasive disease free survival of all randomized participants.,
266,PUMCH-BC502,,200,"immune inflammation-related protein complexes, blood markers",
267,33293720.9.0000.5505,,60,Improvements in heart rate variability indices and rate of perceived exertion after intervention with telerehabilitation.,
268,19-045,,194,Number of participants with treatment-related adverse events as assessed by CTCAE v4.0,
269,199080,,100000,To compare the cost effectiveness of breast cancer screening with digital breast tomosynthesis and 2DDM vs standard screening with 2DDM,
270,SCHBCC-N024,,186,"Stage 1: Effectiveness of cryo-ablation, Stage 2: LRFS(local-regional free survival), Stage 2: Effectiveness of cryo-ablation (3 months after cryo-ablation)",
271,SOLTI-1907,,55,Overall Response rate,
272,4817,,10,Breast somatic mutations,
273,EEBC,,1000,"5-y DFS, 5-y BCSS",
274,symptom of breast cancer,,120,"Trajectory of Symptom distress, Trajectory of fatigue, Trajectory of distress temperature, Trajectory of Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B), Trajectory of PHQ-4: Validated Screening Tool for Anxiety and Depression, Trajectory of ISI: Insomnia Severity Index",
275,APHP211502,,189,Proportion of patient with a compliance to the Personalized Prevention Plan established during the initial risk assessment consultation.,
276,IEO 0761/,,264,"Prevalence of mutations in breast cancer risk-associated genes, Genetic test turnaround time, Percentage of informative specimens",
277,SDS-HER-01-2018,,18,Preliminary determination of HER2 receptor concentration ranges detected with inPROBE corresponding to HER2 receptor status (positive/negative) as determined by current diagnostic standard (IHC/FISH).,
278,ISTMET-BHWGI2022-1,,40,Survival,
279,SLN SPECT,,4,Role of SPECT/CT in sentinel lymph node detection in breast cancer,
280,Cpetptmrbc,,72,identification of recurrence,
281,Tiresias,,150,Progression free survival,
282,RWD_abemaciclib,,108,Progression-free survival,
283,ML40952,,300,Work Productivity and Activity Impairment,
284,CELC-G-301,,701,Progression Free Survival (PFS) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer,
285,CARMA-2101,,100,"Antitumor activity of the CAR-macrophages against organoids from HER2 negative, HER2 low and HER2 positive breast cancers, Antitumor activity of the CAR-macrophages compared to non-modified macrophages",
286,A5481125,,847,"Description of patients demographics receiving Palbociclib, Clinical characteristics of patients receiving Palbociclib, Adjuvant therapies received for the treatment of early or locally advanced breast cancer (Stages 0-IIIa), To describe treatments received in the advanced/ metastatic setting, before and after palbociclib combination use., Percentage of Participants With Reduced Doses of Palbociclib, Percentage of Participants With Dose interruption of Palbociclib, Percentage of Participants With discontinuation of Palbociclib, Percentage of Participants With Delay Doses of Palbociclib, Supportive therapies received by patients while receiving palbociclib combination treatments, Proportion of patients who are progression free at multiple intervals (e.g.12, 18 months), Proportion of patients with Objective response rate (ORR), Overall survival rate",
287,20-1789.cc,,100,"Determine changes in sexual well-being for women with breast cancer, Determine educational resources currently used for sexual health information, Determine educational resources currently used for sexual health information, Determine patients preferred type of education for sexual health",
288,DBCG Proton trial,,1502,Radiation associated ischaemic and valvular heart disease,
289,710/2021,,30,"arm circumference measurement, arm circumference measurement, arm circumference measurement, lymphedema symptom, lymphedema symptom, lymphedema symptom, self-care",
290,OOTR-N016/KBCRN-B-003/HT-PAB,,141,"Pre-operative Endocrine Prognostic Index (PEPI Score), EndoPredictâ¢ EPclin Score",
291,19-003028,,400,Specificity of ultrasound in detection of breast cancer,
292,V2_16-04-2020,,400,Sonographic detection rate of clip at the time of surgery after completion of NST,
293,N19ASC,,340,Axillary recurrence,
294,SNBvsPET/MRI 2,,247,SNB vs PET/MRI,
295,dingxwyh01,,50,ORR(CR+PR),
296,KL166-IIS-001,,48,Objective response rateï¼ORRï¼,
297,SNUH_FMI,,200,Genetic characteristic of young (<50 years of age) Korean patients with metastatic breast cancer.,
298,RF-2013-02358165,,300,Incidence of Breast Cancer Related Lymphedema (BCRL) after Axillary Lymph Node Dissection (ALND),
299,2022/0035986,,25,"interception, acceptation, adherence, lost to follow-up, satisfaction rate, RTW/work continuation",
300,dingxwyh02,,50,ORR(CR+PR),
301,18-516,,47,"Overall Response Rate in the CNS, To evaluate the correlation between inhibition of p-4EBP1 in resected brain tumor tissue and intracranial response in the corresponding patient-derived xenograft (PDX) models of BCBM",
302,17/0765,,240,Number of biopsies collected,
303,AURORA,,20,Complete Radiological Response,
304,2022106,,420,"PFS, AE",
305,BR02/03/21,,26,Objective response rate measured by RECIST 1.1 criteria to anti-cancer therapy selected by QPOP (prospective analysis).,
306,19-147,,6,Incidence of Treatment-Emergent Adverse Events as assessed by CTCAE v5.0,
307,1186,,700,number of SNPs associated with breast cancer,
308,19 SEIN 14,,45,Rate of patients who do not fail the E-Monitoring protocol,
309,01-2021,,1000,To describe treatment sequences of all lines of therapy received by HER2 + mBC patients in Moscow,
310,2018-9529,,75,Tumor permeability assessed by TMEM-MRI,
311,REaCT-HER TIME,,20,"Multiple site activation, Medical oncologist active participation, Enrolment of at least 50 participants across all sites within 9 months of the fourth site accruing its first participant",
312,FLA 18-057,,35,"Mammogram findings before and after intervention: BI-RADS, Mammogram findings before and after intervention:LIBRA, Inflammatory markers before and after intervention: C-reactive protein, Inflammatory markers before and after intervention: Interleukin-6, Inflammatory markers before and after intervention: Insulin Growth Factor-1 (IGF-1), Inflammatory markers before and after intervention: Tumor Necrosis, Breast cancer risk calculation, Biometric measurements: weight, Biometric measurements: Height, Biometric measurements: Body mass index, Biometric measurements: Waist circumference.",
313,HERdi PREDICT,,40,Compare HER2-HER3 dimer expression as detected by FLIM-FRET (% positive for HER2-HER3 dimer expression with FRET efficiency â¥8.56%) to HER2 over-expression (% positive for HER2 over-expression by IHC Â± FISH) in patient-derived tumour samples.,
314,SOLTI-1911,,530,Distant metastasis-free survival (DMFS) in the ROR-low cohort (responder cohort),
315,D9673R00011,,3200,The Prevalence of different HER2 expression levels,
316,IC 2018-08,,405,Psychosocial Assessment in Hereditary Cancer questionnaire (PAHC).,
317,Breast Cancer,,78,Serum cytokine levels,
318,APHP211593,,220,Diagnostic performances,
319,AHQU-2021006,,59,Changes in arthralgia scores were measured by the BPI,
320,V2011201,Decided to halt and will potentially reopen in the future.,0,Efficacy of sabizabulin in the treatment of estrogen receptor positive (ER+HER2) metastatic breast cancer (MBC),
321,Shengjing-LCG009,,30,Residual tumor burden (RCB) classification in grades,
322,HCB-ONC001 (ML41519),,17,To evaluate the possibility of omission of surgery and sentinel lymph node dissection in clinically low-risk HER2-positive breast cancer with high HER2 addiction and a complete response following standard neoadjuvant chemotherapy and dual HER2 blockade.,
323,IAyas2,,30,"FIT-HaNSA test for upper extremity performance, Upper extremity disability, Upper extremity functionality, Shoulder disability",
324,IRB-300002157,,40,Toxicity levels of 1-3 fractions SBRT for partial breast irradiation assessed by CTCAE v4.0,
325,SOC.04/20-21,,3000,"Invasive breast cancer at 3 years following atypia diagnosis, Invasive breast cancer at 6 years following atypia diagnosis",
326,BC001,,354,Patient Health Questionnaire-9 (PHQ-9),
327,OTT-19-06,,40,Complete cell cycle arrest (CCCA),
328,A5481176,,1,"Progression-free Survival (PFS) of patients receiving palbociclib in combination with aromatase inhibitor (AI), Time on Treatment (ToT) of patients receiving palbociclib in combination with aromatase inhibitor (AI)",
329,20210312,,3000,The percentage of guideline-consistent and personalized EBM recommendations,
330,19-509,,400,"Change in patients assessment of their personal contralateral breast cancer risk"", ""Change in patients propensity to choose bilateral mastectomy as determined by a short self-developed survey question",
331,Sentinel lymph node biopsy,,40,Oncologic safety of sentinel node biopsy in clinically palpable axillary lymph node in breast cancer patients,
332,UT BCS ECS Study,Due to COVID this trial never got up and running.,0,Change in Fatigue Scores (Revised Piper Fatigue Scale),
333,oddie2,,32714,â¢ Diagnostic accuracy with difference between breast radiologists with and without AI-based CADe/x,
334,FMASU R61/2020,,300,The percentage of breast cancer patients who accept to participate in clinical trials,
335,UW 20-064,,30,Successful localization of breast tumor and axillary lymph node,
336,18-109,,42,"Discontinuation rate of flibanserin in women with breast cancer on Tamoxifen with disease or medical induced hypoactive sexual desire disorder, Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of flibanserin",
337,19-277,,34,Safety as assessed by CTCAE,
338,FAST feasibility in CU,,20,"Change in cosmetic breast appearance, Acute radiation toxicity assessment, Patient quality of life assessment., Patient satisfaction.",
339,UC-0105/1701,Study was halted Prematurely for low recruitment.,31,progression-free survival,
340,20-1039,,112,"Change in Self-Reported Patient Sexual Function, Change in Self-Reported Patient Sexual Distress, Change in Patient Self-Reported Self-Efficacy for Coping with Sexual Concerns",
341,BRAR1,,112,"Receptor expression, BRCA1 and BRCA2 mutations",
342,18-1025,,240,Change in Self-Reported Patient Sexual Function,
343,IRB16-0396,,200,True Positive,
344,09.2019.984,,22,"Arm circumference difference, Arm circumference difference, Arm circumference difference, Arm circumference difference, Subcutaneous echogenicity grade (SEG), Subcutaneous echogenicity grade (SEG), Subcutaneous echogenicity grade (SEG), Subcutaneous echogenicity grade (SEG), Subcutaneous echo-free space (SEFS) grade, Subcutaneous echo-free space (SEFS) grade, Subcutaneous echo-free space (SEFS) grade, Subcutaneous echo-free space (SEFS) grade, shoulder range of motion (ROM) will be evaluated with a goniometer, shoulder range of motion (ROM) will be evaluated with a goniometer, shoulder range of motion (ROM) will be evaluated with a goniometer, shoulder range of motion (ROM) will be evaluated with a goniometer, Pain, tightness and heaviness sensation, Pain, tightness and heaviness sensation, Pain, tightness and heaviness sensation, Pain, tightness and heaviness sensation",
345,O4M-B001,,125,Measure # of times a patient logs into the Outcomes4Me app over a 12 week period,
346,STGKS001,,55579,"Incident breast cancer, Incident breast cancer, Incident breast cancer",
347,TaiHao TVGH2020-07-006AC#1,,3,"The average performance of the 4 machines, in terms of sensitivity for detecting suspicious breast cancer, is not inferior to Siemens performance.",
348,CNER 202107/05,,15,"Acceptability of medication adherence support tool, Quality of medication adherence support tool, Medication Adherence",
349,Optimune Trial,Participant recruitment was stopped due to corona pandemic.,64,"concentration of C-reactive protein (CRP), circulating Interleukin (IL) 6, circulating Tumor necrosis factor (TNF)-Î±, stimulated IL-6, stimulated TNF-Î±",
350,19-086,,77,Incidence of Treatment-Emergent Adverse Events,
351,Emotional security&mastectomy,,143,Quality of life post mastectomy,
352,1808019498,,100,"Tolerability will be demonstrated if no grade 3 or higher toxicities are observed in the first 8 patients, of each arm., Clinical response rate to tumor radiation +/-immunotherapy during standard endocrine therapy for HR+ breast cancer will be measured., Pathological response rate to tumor radiation +/-immunotherapy during standard endocrine therapy for HR+ breast cancer will be measured.",
353,HYGEE,,27,"Evaluate, in patients undergoing chemotherapy for the treatment of breast cancer, the impact of the use of hypnotherapy performed by a virtual reality tool on the anxiety felt just before the PAC procedure.",
354,Breast Audit,,690,"Demographic characteristics of patients with breast cancer, Risk factors of patients with breast cancer, Clinical presentation of patients with breast cancer, Stage of the breast cancer, Histopathological characteristics of patients with breast cancer",
355,STU-2018-0370,,11,"Spatial location of breast tumors, 3-D Surface contour maps of the breast, Computational thermal model of breast cancer",
356,A5481115,,1,"Demographic and clinical characteristics of ABC patients at the initiation of treatment with palbociclib, Treatment patterns of palbociclib, including line of therapy and type of endocrine therapy combined with palbociclib, and initial dosage, Time to treatment failure (TTF) of palbociclib in combination with endocrine therapy by the line of therapy, Treatment patterns of subsequent therapy after end of palbociclib treatment, including line of therapy and type of treatment, TTF of subsequent therapy after end of palbociclib treatment, Changes in treatment pattern before and after the launch of palbociclib, the revision of clinical guideline in Japan, Use of antibiotics and/or granulocyte-colony stimulating factor (G-CSF) during treatment with palbociclib, Frequency of blood tests during treatment with palbociclib",
357,Prix Ruban Rose/2021/FF-01,,20,"Specific needs of patients who have undergone breast cancer surgery : ePRO results, Use of ePROs as a means of collecting post-surgical complications, Results of the interview with the nurse for collecting post-surgical complications, Actions desired in the event of an onset of complications in patients who have undergone breast cancer surgery., Degree of anxiety/reassurance of patients who have undergone breast cancer surgery., Expectations of patients who have undergone breast cancer surgery.",
358,MRI in breast cancer,,45,comparison of MRI findings with pathologic results,
359,Pyrotinib neoadjuvant,,80,tpCR rate (ypT0/is ypN0),
360,SMC 2021-02-102,,178,5-year recurrence free survival,
361,BSMMU/2019/8874,,80,To measure the serum level of MDA and RBC glutathione in breast cancer patients receiving chemotherapy and following administration of vitamin C and vitamin E concurrent to chemotherapy.,
362,FUSCC-OMIT,,172,Overall Survival,
363,20210601,,100,Pathologic complete response in the breast and lymph nodes (ypT0/Tis ypN0),
364,Telemonitoring BCS,,30,"Upper Limb Functionality, Assessment of quality of life",
365,CCTG MA.39,,2140,compare the breast cancer recurrence-free interval (BCRFI) between patients that received regional RT or not,
366,99mTc-ADAPT6 vs 99mTc-DARPinG3,,15,"99mTc-ADAPT6 uptake (counts)/SUV, 99mTc-ADAPT6 tumor-to-background ratio (SPECT), 99mTc-DARPinG3 uptake (counts)/SUV, 99mTc-DARPinG3 tumor-to-background ratio (SPECT), 99mTc-ADAPT6 vs 99mTc-DARPinG3 uptake (counts)/SUV, 99mTc-ADAPT6 vs 99mTc-DARPinG3 tumor-to-background ratio (SPECT)",
367,2021-1116,,400,disease free survival,
368,2490,,105,"EVs levels in early BC, EVs levels in metastatic BC",
369,IRB-2022-166,,1000,SREs,
370,19/317-2101,,2000,disease-free survival,
371,s66248-aim2,,150,"Reliability of measurements with MyotonPro, Validity of the evaluation tool for Myofascial Adhesions in Patients after Breast Cancer, Validity of palpation for general stiffness, Reliability for the assessment of movement functions, Construct validity for the assessment of movement functions, Validity of machine learning model for Upper limb functioning from ActiGraph sensors for breast cancer survivors, Validity of the use of hot/cold tubes for temperature sensations, Validity of the assessment of upper limb activities through accelerometry, Validity of the assessment of upper limb activities: quickDASH",
372,SPT-2021-002,,70,Progression free survival (PFS),
373,Cardiac safety study,,30,Time ending,
374,BGB-290-201,,88,Objective Response Rate (ORR) as Assessed by Independent Radiology Review (IRC),"Death, ""Sponsors Decision"", Withdrawal by Subject, Lost to Follow-up"
375,EORTC 1745-ETF-BCG,,366,distant recurrence-free interval (D-RFI) rate,
376,10038,,69,Incidence of Adverse Events,
377,Pro00085352,,6,Change in tumor infiltrating immune cells,
378,4523,,90,Reduction of frequency and intensity of hot flashes following acupuncture treatment,
379,01AB21- PIK3CA,,40,"Phase Ib Safety and Tolerability of alpelisib and tucatinib combination, summary of all AEs and SAEs on study as evaluated by NCI-CTCAE v 5.0, Phase II Efficacy of tucatinib combination evaluated by progression free survival (PFS)",
380,Optimune Trial Add-on,,360,"Determination of Quality of Life using the WHOQOL-BREF, Determination of Physical Activity using the International Physical Activity Questionnaire, Determination of Diet Quality using the Food Quality Questionnaire",
381,2018396H,,200,pCR,
382,2004-261-112,due to poor enrolled patients,3,response rate of neoadjuvant chemotherapy,
383,ICO-N-2017-12,,300,"Creation of complex prospective clinico-biological database in metastatic breast cancer, Creation of complex prospective clinico-biological database in metastatic breast cancer, Overall survival",
384,17-455,,100,Progression Free Survival,
385,69HCL18_0310,,32,The evolution of the quality of life,
386,IJB-NERABRAIN-ODN-007,Termination of collaboration with PUMA,0,"For cohort1: Efficacy of neratinib in combination with systemic treatment at investigators choice in preventing the next CNS event in HER2 breast cancer with known and treated brain metastasis"", ""For cohort 2: Efficacy of neratinib in combination with systemic treatment at investigators choice on previously untreated brain metastasis from HER2 metastatic breast cancer"", ""For cohort 3: Efficacy of neratinib in combination with systemic treatment at investigators choice on LM disease from HER2 metastatic breast cancer",
387,APHP190505,,80,Percentages of fetal cells in each immune cell subpopulation.,
388,19-066,,214,"Neurologic Quality of Life at 12 Months using the MD Anderson Symptom Inventory - Brain Tumor Module, Incidence of Symptomatic Brain Metastases, Incidence of Brain Metastases",
389,GEICAM/2019-01,,200,Residual Cancer Burden (RCB) 0-I rate,
390,MA-BC-â¡-040,,35,"Complete cell-cycle arrest at C1D15, defined as ki67â¤2.7%",
391,PROICM 2020-05 SKY,,108,"the efficacy of a combined intervention of physical therapy and yoga, including patient education with a control group for confirmed osteoarticular and/or musculoskeletal pain (â¥4) due to hormone therapy in patients treated for breast cancer.",
392,EH18-203,,22,"Acceptability of a mindfulness intervention prior to the surgical consultation measured by adherence to the intervention., Acceptability of a mindfulness intervention following the surgical consultation measured by adherence to the follow up session., Participant feedback via Questionnaire on the usefulness of the mindfulness experience on their emotional management and decision making process., Feasibility of a mindfulness intervention prior to the surgical consultation by a single question regarding mode of communication participants prefer., Feasibility of a mindfulness intervention prior to the surgical consultation by calculating proportion of participants who consent to the study., Feasibility of a mindfulness intervention prior to the surgical consultation by proportion of participants who have contact with the mindfulness teacher., Feasibility of a mindfulness intervention prior to the surgical consultation by measuring the length of time to schedule the participant with the mindfulness teacher., Feasibility of a mindfulness intervention prior to the surgical consultation by adherence to the mindfulness excercises.",
393,2019-1183,,70,Reach the maximum tolerated dose (MTD),
394,A211801,,300,Time to the occurrence of any breast cancer (invasive or ductal carcinoma in situ [DCIS]),
395,BakircayU,,111,Hand-Grip Strength,
396,SGK-SFC-001,,200000,"Engage participants representative of the United States breast cancer patient population in ShareForCures., Integrate participant data into ShareForCures., Facilitate scientific research using ShareForCures data.",
397,22-280,,100,"Change in serum carboxy-terminal collagen crosslinks (CTX), Change in bone specific alkaline phosphatase (ALK)",
398,SOC.03/20-21,,10000000,"Breast Cancer Specific Mortality, Breast Cancer Specific Mortality, Breast Cancer Specific Mortality, All cause mortality, All cause mortality, All cause mortality, Overdiagnosis, Overdiagnosis, Overdiagnosis, Stage Shift, Treatment Received, False positive recall to assessment",
399,CAAE: 39277420.8.0000.5313,,36,Change from Baseline Cancer-related fatigue at 3 months,
400,5354-CL-1201,,132,Optimal dose of ASP5354 for lymph node (LN) visualization,
401,800646,,135,Medical record review of engagement in goal-concordant oncofertility care,
402,D361DC00001,,700,"Phase Ib: 1. The number of participants with dose-limiting toxicity, as defined in the protocol., Phase Ib: 2. The number of participants with treatment-related adverse events., Phase Ib: 3. The number of participants with treatment-related serious adverse events., Phase III: 1. Progression Free Survival (PFS).",
403,2019-228,,323,Contralateral breast cancer,
404,PekingUMCH-NM25,,34,Standardized uptake value of 99mTc-HPArk2 in breast tumor,
405,MO39485,,2907,Percentage of Participants with Different Breast Cancer Subtypes at Diagnosis in Latin America,
406,BCP28,,218,The features of CT-based radiomics for axillary lymph node achieved pCR after neoadjuvant chemotherapy,
407,DARE,,100,"Surveillance/ctDNA screening Phase, Therapeutic Phase",
408,NP 1521/19,,86,The incidence and change of endocrine dysfunction.,
409,NOV2016PhD818,,41,"Number of participants with self-reported outcome data at 12 weeks., Proportion of missing data in self-report outcome questionnaires., Appropriateness of each of the self-report outcome questionnaires by assessing ceiling and floor effects (EQ-5D-5L)., Appropriateness of each of the self-report outcome questionnaires by assessing ceiling and floor effects (FACT-B)., Appropriateness of each of the self-report outcome questionnaires by assessing ceiling and floor effects (B-CBI)., Appropriateness of each of the self-report outcome questionnaires by assessing ceiling and floor effects (SEMCD-6)., Acceptability & use of intervention: Number of symptom monitoring reports generated and qualitative interview data.",
410,M2020 UK01,,1000,"BREATH TEST TO PREDICT BREAST CANCER, BREATH TEST TO PREDICT OUTCOME OF MAMMOGRAPHY",
411,TRA05-GEFPICS,,155,To assess the reproducibility of the IHC4 score testing performed in local pathology laboratory (i.e. real life) to in a central laboratory.,
412,ATADEK-2021/14/16,,180,"Tampa Kinesiophobia Scale, Questionnaire on exercise barriers, INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRES (IPAQ)",
413,[2019]52,,10,"Visual Assessment of HER2 expression in Breast cancer using 99mTc-NM-02 SPECT/CT Scan, Semiquantitative Assessment of Breast and other Metastatic Lesions in 99mTc-NM-02 SPECT/CT Scan, Safety of 99mTc-NM02 through Adverse Event Monitoring, Safety of 99m-Tc-NM-02 through Adverse Event Monitoring",
414,EudraCT 2020-005200-19,,40,To determine the proportion of patients that convert to ER expressing breast cancer,
415,GEICAM/2017-01_IBCSG 62-20_BIG,,300,Progression Free Survival (PFS),
416,J21125,,450,"Prevalence of prediabetes, Prevalence of diabetes, Prevalence of hyperlipidemia, Change in HbA1c, Change in LDL cholesterol, Prevalence of obesity/ overweight, Quality of Life Questionnaire The European Organisation for Research and Treatment Cancer C30, Breast-specific symptoms assessed by the of The European Organisation for Research and Treatment Cancer Quality of Life Questionnaire BR-23",
417,PekingUMCH-FES-BC-1,,50,"Standardized uptake value of 18F-FES in BC, Lesions detected by 18F-FES PET/CT, Compared with 18F-FDG PET/CT",
418,D9673C00007,,500,"Objective Response Rate (ORR) in Participants without BM at Baseline (Cohort 1), Progression-free Survival (PFS) in Participants with BM at Baseline (Cohort 2)",
419,GCO 17-00563,,60,Illness Perceptions Questionnaire (IPQ scores),
420,LY2022-028-B,,488,Pathologic Complete Response,
421,18ON009,,4750,Production of a SPAG5 assay,
422,MD.21.09.521.R,,30,prediction of axillary lymph nodes status,
423,TQB3616-III-03,,1946,Invasive Disease-Free Survival (IDFS),
424,20190283,,18,Recommended Phase 2 Dose (RP2D) of Pre-Operative SABER,
425,SPHIC-TR-BCa2022-01,,24,Acute toxicity,
426,UBRS20139,,22,"overall survival, CNS progression free survival",
427,2018-9567,,20,Total adipose tissue (TAT),
428,FISH in breast cancer,,40,Detection of chromosome 10q23 deletion including PTEN locus in breast cancer patients.,
429,20 SEIN 13,,200,Rate of patients who adhere to tamoxifen treatment.,
430,201819010.4,,100,"The frequency of the genetic polymorphisms of CYP2C19 in breast cancer patients, The frequency of the genetic polymorphisms of ALDH3A1 in breast cancer patients",
431,DBCG RT Recon,,590,Number of patients with complications with surgical intervention,
432,NCC3075,,60,Primary Endpoint,
433,CSPC-DMS-BC-13,,1213,"Pathological complete remission (pCR), Disease-free survival ï¼DFSï¼",
434,2018NTLS176,,40,Complete Pathologic Response (pCR),
435,ChanghaiHTB,,362,Overall survival,
436,BrIMA,,160,Perioperative addressing positive margins of the invasive component in IDC.,
437,PROICM 2019-11 PRA,,400,Impact of Pravastatin on the occurrence of grade â¥2 breast fibrosis in a selected breast cancer patient population considered at high risk of severe breast fibrosis occurrence,
438,19900601,,108,"Changes in breast cancer-related lymphedema at baseline,9 weeks after surgery,and 18 weeks after surgery",
439,FDRT-BC009,,170,intracranial local tumor control rate,
440,SRMBCNabP2022,,30,pathologic complete response (pCR) rate,
441,BCHRD201,,100,Complete pathological response of breast and lymph nodes (ypT0/is ypN0; defined as no microscopic evidence of residual invasive viable tumor cells in all resected specimens of the breast and axilla),
442,21-3576.cc,,50,"Predicted patient reported outcomes up to 1 year after, Actual patient reported outcomes for each domain after surgery, Compare predicted and actual outcomes, Patients preferred method of communicating results",
443,MCC-20897,,30,Maximum Tolerated Dose (MTD),
444,C3441020,This study was terminated based on Pfizers change in clinical development strategy not related to safety and efficacy.,61,"Percentage of Participants Achieving Pathological Complete Response (pCR) as Per Independent Central Review (ICR) in Evaluable Analysis Set as Per ICR With 80% Confidence Interval (CI), Percentage of Participants Achieving pCR as Per ICR in Evaluable Analysis Set as Per ICR With 95% CI","Adverse Event, Progressive Disease, Other, Withdrawal by Subject, Death, Study Terminated By Sponsor, Withdrawal by Subject"
445,IIT2018-01-McArthur-IPI,,80,Event-Free Survival,
446,18-223,,10,"Maximum Tolerated Dose, Recommended Phase II dose (RPIID), Objective Response Rate",
447,2018-00838; ch20Weber2,,1500,Disease-free survival (DFS),
448,2019/FO244363,,4000,QALY (Quality-Adjusted-Life-Year),
449,KYJJ-2021-186,,1000,iDFS,
450,UC-0107/1903,,250,"Patients choice when de-escalation is proposed between whole breast radiotherapy (WBRT), Intra Operative Radiotherapy (IORT) or no radiotherapy (RT).",
451,AB-MR for Second Breast Cancer,,1564,Sensitivity and Specificity (co-primary),
452,WSG-AM09,,46,Evaluation of the pCR rate of the combination therapy consisting of pembrolizumab in combination with the dual anti-HER2 blockade trastuzumab biosimilar ABP 980 and pertuzumab in patients with HER2-enriched early breast cancer assessed by PAM50 testing,
453,18-058,,42,"differences in DNA somatic mutational profile, differences in RNA sequencing",
454,PANONC-1 Version: 1.1,,300,pathological complete remission rate,
455,AHQU-2021005,,54,FACT/GOG-Ntx,
456,BC-2019,,300,"dose distribution of GTV, dose distribution of CTV, dose distribution of PTV, dose distribution of heart, dose distribution of ipsilateral lung, dose distribution of bilateral breasts",
457,SP00049673,,49,"Number of Participants Retained During the 12 Week Technology Supported Physical Activity Intervention Period, Adherence to a 12 Week Technology Supported Physical Activity Intervention by Metastatic Breast Cancer Patients, Acceptability of a 12 Week Technology Supported Physical Activity Intervention to Metastatic Breast Cancer Patients",Death
458,BCSCO003,,20000,"Breast-conserving surgery rate,, Breast-conserving surgery rate, sentinel lymph node biopsy rate",
459,DSCN-EHT-NIS-BC001,,1000,"Percentage of Participants Receiving Each Regimen in Each Treatment Line, Treatment Sequence Since the Time of Diagnosis of HER2-positive Unresectable or Metastatic Breast Cancer, Percentage of Participants Receiving Endocrine Therapy if Breast Cancer is Hormone Receptor Positive, Percentage of Participants Receiving Local and Regional Treatment for Metastasis (Radiotherapy and/or Surgery) and Osteoprotective Therapy",
460,19-188,,30,Median Progression Free Survival,
461,LC2019L06,,286,RFS,
462,SCBCS025,,34,Objective response rate in the CNS,
463,17-512,,78,Progression-free Survival,"Complete response, Intercurrent illness, Progressive Disease, Adverse Event, Physician Decision, Withdrawal by Subject, ""Patient proceeded with chest wall excision"", ""Participant needed palliative radiation, which is not permitted on study"", Still on treatment, Never started protocol therapy, Progressive disease, Adverse Event, Physician Decision, Still on treatment"
464,Breast Screening with DWI,,890,Sensitivity,
465,19-239,,75,Dose Limiting Toxicity,
466,ICO-2019-03,,132,Assess the prognostic value of the texture parameters of PET-TDM FDG on event-free survival at 2 years.,
467,GEICAM/2016-03,,8000,"Event Free Survival (EvFS) in neoadjuvant studies., Disease Free Survival (DFS) in adjuvant studies.",
468,HNCH-BC003,"In clinical treatment, most patients with stage IV breast cancer received surgical treatment, which made it difficult to enroll this project, so this study was terminated.",0,OS,
469,State University of SÃ£o Paulo,,6,Evaluation of body composition by Bone Densitometry (DEXA) equipment,
470,02AB21-TucErBit,,30,"To assess the safety and tolerability of tucatinib in combination with eribulin and trastuzumab in patients with unresectable or recurrent metastatic HER2+ breast cancer who have had prior treatment with trastuzumab, and trastuzumab deruxtecan., Evaluate the relative toxicity/tolerability of these therapeutic agents when used in combination in this patient cohort",
471,21-183,,78,evaluate rates of axillary lymph node dissection,
472,IRB-48150,Logistics,20,Detection of ER positive breast cancer and metastases on 68-Ga RM2 PET/MRI,
473,Breast Cancer Screening,,1694,Cancer detection rate (CDR),
474,Soh-Med-23-01-07,,90,"serum level of Ca15-3, serum level of interferon gamma",
475,D133FR00138,,436,"Proportion of patients with ER positive, HER2 negative locally advanced or metastatic breast cancer assigned to each treatment modality used as the first line of treatment., Characteristics of patients in each treatment modality according to their histologic diagnosis, Hormone sensitivity, visceral vs non-visceral disease proportion, reason for selecting the treatment.",
476,IUSCC-0613,,18,Safety of Gedatolisb + PTK7-ADC using NCI CTCAE v4.0,
477,21-440,,20,"Number of eligible patients completing initial MRI, Percentage of eligible patients completing cerebrospinal fluid (CSF) evaluation",
478,GEICAM/2020-08,,49,Objective Response Rate (ORR),
479,2023-09,,50,The reliability of the use of Spot Endoscopic Marker,
480,16-145,,98,Rate of recommendation for repeat surgery on postoperative histopathology,
481,ZNJC201935,,600,"Rate of arm lymphedema, Rate of locoregional recurrence, Rate of distant metastasis",
482,YM107109E,,112,"Baseline EORTC QLQ-C30, Change of EORTC QLQ-C30 at 1.5 month, Change of EORTC QLQ-C30 at 3 month",
483,A5481144,"The study was prematurely discontinued due to significant data quality issues on August 26, 2021. There were no safety concerns that led to the decision to terminate.",975,"Number of Participants With Different Type of Treatment Regimens, Number of Participants Who Received Different Treatment Sequence Across Lines, Number of Participants With Start and End Dose of CDK4/6 Inhibitors, Duration of Treatment of CDK4/6 Inhibitors, Number of Participants With Reason for Treatment Discontinuation of CDK4/6 Inhibitors, Time to Dose Discontinuation of CDK4/6 Inhibitors, Number of Participants With Type of Dose Adjustments of CDK4/6 Inhibitors, Time to First Dose Adjustment of CDK4/6 Inhibitors, Real Progression Free Survival (rwPFS), Overall Survival (OS), Real-World Tumor Response (rwTR), Percentage of Participants With Complete Response (CR) or Partial Response (PR), Time to First Positive Response, Duration of Response (DOR), Duration of Initial Endocrine-based Treatment, Duration of Treatment, Duration of Follow-up",Premature termination of study
484,grid.412416.4,,275,Interleukin-7,
485,MA-BC-II-024,,420,"pCR rate using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) at the time of definitive surgery",
486,18-333,,30,Determining whether DBT-TOBI total hemoglobin concentration measurements before cycle 3 of chemotherapy can predict pathological complete response (pCR) versus non-complete responses in breast cancer.,
487,ARV-471-BC-201,,150,"Evaluate the effects of ARV-471 and anastrozole, respectively, on Ki-67 expression in tumors after 2 weeks of treatment",
488,2018-09-007A,,1875,"The rate of genomic alteration, Clinical outcome",
489,ML42450,,1331,"Treatment outcome data: Overall survival (OS), Treatment outcome data: Progression-free survival (PFS)",
490,intestinal flora study,,50,"The quantity of intestinal flora from breast cancer patients fecal microflora at different follow-up nodes"", ""The abundance of intestinal flora from breast cancer patients fecal microflora at different follow-up nodes",
491,Microbiome_BC&PnC,,35,Intestinal bacterial structure in BC and PnC (separately) patients with disease progression,
492,DS8201-A-U301,,600,Progression-free survival (PFS) based on blinded independent central review (BICR),
493,M18DMB,,12,The objective response rate (ORR),
494,2017MayPR898,,74,Fear of Recurrence level - FCR7,
495,MUKDEN-09,,236,Pathologic Complete Response Rate (tpCR: ypT0-is/ypN0),
496,R148/2021,,270,Assessment of TIL relation to pathologic complete response,
497,SSGJ-302H-mBC-IIT-01,,60,"Cmax, Cmin, AUC0-t, AUCtau",
498,SCHBCC0N026,,20,pathologic Complete Response (pCR),
499,21-003046,,50,Differences in tumor microenvironment subpopulations in aromatase inhibitor (AI)-sensitive version (vs.) AI-resistant hormone receptor (HR)+ breast cancer,
500,GNC-035-103,,29,"DLT, MTD or MAD, TEAE, The recommended dose for future clinical study, RP2D",
501,KY2019-070,,316,Invasive Disease-free Survival (iDFS),
502,NCC 2019-0098,,130,reduction of body mass index (BMI),
503,NACAGEP,,20,De-escalation of breast cancer surgery,
504,CINDERELLA,,1030,"Agreement between patients expectations before and after treatment in both the intervention and the control arm., Agreement about the aesthetic outcome between the objective evaluation and self- evaluation measured after treatment in both the intervention and the control arm",
505,310-17-SZMC,,15,"To establish a safe dose of PLD when delivered in combination with pembrolizumab, To evaluate the Tumor Response Rate according to Response Evaluation Criteria in Solid Tumors (RECIST) after 9 weeks (3 cycles) of treatment in patients with measurable disease.",
506,CCR5214,,324,Assess progression free survival (PFS),
507,K2022-025-01,,63,Progression-Free Survival (PFS),
508,PUMCH-MUSD,,6000,screening yield,
509,1R01CA236860-01A1,,250,"Change in Physical Symptoms, Change in Perceived Stress, Change in Medication Adherence, Change in Self-Reported Medication Adherence, Health-Related Quality of Life in Breast Cancer Patients as assessed by the Functional Assessment of Cancer Therapy - Breast Cancer, Neural Activity to the Affirmation Task, Neural Activity to Stressful Task, Functional Neural Activity to Positive Stimuli, Functional Neural Activity to Negative Stimuli, Change in Perceived Stress, Change in Bodily Pain as assessed by the RAND 36-Item Health Survey 1.0, Change in Self-Reported Medication Adherence",
510,D8530C00001,,403,"The number of subjects with dose-limiting toxicity, as defined in the protocol., The number of subjects with treatment-related adverse events as assessed by CTCAE v4.03.",
511,RGT-419B_01-101,,48,Safety & Tolerability - Number of subjects with Dose-Limiting Toxicities (DLTs) at each cohort dose level in singlet and doublet therapy,
512,APHP191059,,204,Positive predictive value (PPV),
513,BT006,,10,Adverse events,
514,2017-01282 (BASEC),recruitment difficulties,1,Accuracy of MRI as Method for Assessment of Quantitative Treatment Success (Correlation With Results of the Histopathological Analysis Performed as Reference Method),
515,MCC-21757,,86,Local Control,
516,A5481155,,242,"Percentage of Participants With Treatment Regimen Distribution, Percentage of Participants With Sequence of Treatment Lines, Percentage of Participants With Their Starting Dose and End Dose, Percentage of Participants With Type of Dose Adjustment, Percentage of Participants With Their Reason For Treatment Discontinuation, Time to Dose Adjustment, Probability of Real-World Progression-Free Survival (rwPFS) at Month 3, Probability of Real-World Progression-Free Survival (rwPFS) at Month 6, Probability of Real-World Progression-Free Survival (rwPFS) at Month 12, Probability of Real-World Progression-Free Survival (rwPFS) at Month 18, Probability of Real-World Progression-Free Survival (rwPFS) at Month 24, Probability of Real-World Progression-Free Survival (rwPFS) at Month 30, Probability of Real-World Progression-Free Survival (rwPFS) at Month 36, Probability of Real-World Overall Survival (rwOS) at Month 3, Probability of Real-World Overall Survival (rwOS) at Month 6, Probability of Real-World Overall Survival (rwOS) at Month 12, Probability of Real-World Overall Survival (rwOS) at Month 18, Probability of Real-World Overall Survival (rwOS) at Month 24, Probability of Real-World Overall Survival (rwOS) at Month 30, Probability of Real-World Overall Survival (rwOS) at Month 36, Probability of Participants Without First Line Treatment Discontinuation or Death at Month 3, Probability of Participants Without First Line Treatment Discontinuation or Death at Month 6, Probability of Participants Without First Line Treatment Discontinuation or Death at Month 12, Probability of Participants Without First Line Treatment Discontinuation or Death at Month 18, Probability of Participants Without First Line Treatment Discontinuation or Death at Month 24, Probability of Participants Without First Line Treatment Discontinuation or Death at Month 30, Probability of Participants Without First Line Treatment Discontinuation or Death at Month 36, Probability of Participants Without Subsequent Line of Therapy Initiation or Death at Month 3, Probability of Participants Without Subsequent Line of Therapy Initiation or Death at Month 6, Probability of Participants Without Subsequent Line of Therapy Initiation or Death at Month 12, Probability of Participants Without Subsequent Line of Therapy Initiation or Death at Month 18, Probability of Participants Without Subsequent Line of Therapy Initiation or Death at Month 24, Probability of Participants Without Subsequent Line of Therapy Initiation or Death at Month 30, Probability of Participants Without Subsequent Line of Therapy Initiation or Death at Month 36, Probability of Participants Without Subsequent Chemotherapy or Death at Month 3, Probability of Participants Without Subsequent Chemotherapy or Death at Month 6, Probability of Participants Without Subsequent Chemotherapy or Death at Month 12, Probability of Participants Without Subsequent Chemotherapy or Death at Month 18, Probability of Participants Without Subsequent Chemotherapy or Death at Month 24, Probability of Participants Without Subsequent Chemotherapy or Death at Month 30, Probability of Participants Without Subsequent Chemotherapy or Death at Month 36, Probability of Participants Without a First Line Therapy Dose Adjustment at Month 3, Probability of Participants Without a First Line Therapy Dose Adjustment at Month 6, Probability of Participants Without a First Line Therapy Dose Adjustment at Month 12, Probability of Participants Without a First Line Therapy Dose Adjustment at Month 18, Probability of Participants Without a First Line Therapy Dose Adjustment at Month 24, Probability of Participants Without a First Line Therapy Dose Adjustment at Month 30, Probability of Participants Without a First Line Therapy Dose Adjustment at Month 36",
517,21822,Lack of accrual,0,"Pathologic complete response (pCR) rate, Adverse events (AEs)",
518,CTNZ-2017-01,,160,Reduce the incidence of delayed CINV in patients receiving adjuvant or neoadjuvant breast cancer chemotherapy,
519,2020-08-06R,,300,"Composite endpoint of cardiac condition, Composite endpoint of quantitative fibrosis assessment, Exercise tolerance",
520,0720222005,,1106,Disease-Free Survival,
521,20-649,,32,Overall response rate (ORR)-RECIST,
522,D967UC00001,,1134,Progression Free Survival (PFS) by Blinded Independent Central Review (BICR) assessment,
523,Qassim QDs-VELD,,30,"Growth inhibition was measured using the sulforhodamine B-based assay., Amount of QDs-VELD fluorescent QDs-VELD in the breast periphery due to the fluorescence of QDs using flow cytometry., Growth inhibition was measured by visual determination of breast cancer cells.",
524,COV-19 BUMDC,,87,"Duration of delay in presentation to hospital, Duration of delay in definitive treatment, Cancer upstaging",
525,PLEASURABLE,,59,"The number of patients in the Phase 1b part of the study with any adverse events (AE)., Objective response rate (ORR)",
526,HR-BLTN-III-EBC,,1192,Invasive Disease-free Survival (iDFS),
527,14-833-02,,153,"Self-Reported Self-Efficacy for Communicating About Sexual Health Issues, Self-Reported Self-Efficacy for Communicating About Sexual Health Issues, Self-Reported Outcome Expectancies for Sexual Health Communication, Self-Reported Outcome Expectancies for Sexual Health Communication, Number of Patients Who Asked at Least One Question About Sexual Health at Their Clinic Visit, Number of Patients Who Initiate Conversation About Sexual Health in Their Clinic Visit","Lost to Follow-up, Withdrawal by Subject"
528,CLUE-BCL,,30,CLUE score,
529,C3441055,,40,Time to treatment failure for talazoparib,
530,2020-A01423-36,,90,"Identification at diagnosis of a plasma protein profile predictive of metastatic relapse in patients with triple-negative breast cancer (TNBC), Identification at diagnosis of a plasma protein profile predictive of metastatic relapse in patients with triple-negative breast cancer (TNBC)",
531,Radiotherapy in Breast Cancer,,100,"detection of breast shrinkage, detection of breast shrinkage, breast on the treated side is indurated, detection of irregularity of breast shape, breast on the treated side is indurated, detection of irregularity of breast shape",
532,CRF-NHI01,,200,Fatigue Improvement,
533,STML-ELA-0222,,322,Determine the recommended Phase 2 dose (RP2D) of elacestrant in combination with each of the other study drugs,
534,17-519,,45,Progression Free Survival,
535,nihan25,,200,"Breast Cancer Screening Beliefs Scale, Health Belief Model Scale in Breast Cancer Screening",
536,H-41818,,34,Objective Response,
537,PRO00034502,"Due to COVID-19 pandemic, we will not be pursuing this study",0,Breast cancer patients relationship with food.,
538,SCLND0919,,180,Disease free survival,
539,2020-0927,,300,To establish the diagnostic performance of Molecular Breast Imaging (MBI) to breast Magnetic Resonance Imaging (MRI) in women who are at high risk of developing breast cancer,
540,2020FES,,8,Sensitivity of parametric FES-PET/CT,
541,AHQU-2021001,,102,Fatigue was measured by Checklist for Individual Strengthï¼CISï¼.,
542,PUMA-NER-6203,,6,Changes in Colon Pathology,
543,Breast cancer in females,,46,Toxicity of concurrent paclitaxel & breast radiotherapy such as acute skin toxicities .,
544,ADA,,160,Health-related quality of life,
545,KBCSG-24,,533,Disease-Free Survival,
546,2018LS148,,40,"Feasibility of Weight Loss Intervention, Acceptability of Weight Loss Intervention",
547,CentroHLOBreastUnit,,90,Tumor Biology,
548,PekingUMCH-BCa093,,50,Diagnostic performance,
549,DBCG RT Natural Trial,,926,Invasive local recurrence,
550,Fenofibrate in Breast Cancer,,50,"Nerve growth factor (NGF) Concentration, Neurofilament light chain (NfL) protein Concentration",
551,514-0213/21-5000,,24,"Insulin sensitivity status, Hepatic glucose production",
552,AHQU-2021003,,34,pCR rate,
553,SYSEC-KY-KS-2021-182,,64,Pathologic characteristic,
554,GCO 21-0699,,60,The Dose-Limiting Toxicity (DLT) and Recommended Phase II Dose (RP2D),
555,IPNCb-01,,30,pathologic complete response (pCR) rate,
556,003-2017,,24,Acute toxicity,
557,CCR4965,,165,Comparison of the change in patient activation (validated questionnaire: Patient Activation Measure (PAM-13) Survey),
558,CASE6119,,30,"Treatment Cohort MTD of Î±-lactalbumin vaccine, Preventative Cohort MTD of a-lactalbumin vaccine",
559,E19137,PI is moving to a new institution,20,Progression free survival,
560,55791222.0.0000.5313,,48,Cancer-related fatigue,
561,CSPC-KAL-BC-12,,250,"the Pathological complete remission(pCR), Disease-free survival (DFS)",
562,NCC2018M-042,,40,Progression-Free Survival (PFS),
563,STU00201961A,,51,"Health Related Quality of Life will be evaluated with The Functional Assessment of Cancer Therapy-Breast (FACT-B), Symptom Burden will be evaluated with The Breast Cancer Prevention Trial symptom questionnaire (BCPT)",
564,18-561,,30,Overall Response Rate of Nivolumab in Combination With Ipilimumab,"Adverse Event, Physician Decision, Withdrawal by Subject, Lack of Efficacy, still on treatment"
565,Breast cancer treatment,,100,"Improvement in the overall response rate, Improvement in the pathological response",
566,UF-BRE-002,institutional conflict of interest,0,"Cmax of Epidiferphanes components"", Rate of occurrence of DLTs by dose level in patients with breast cancer who are being treated with taxanes, Maximum tolerated dose of Epidiferphane in patients with breast cancer who are being treated with taxanes, Cmax of taxanes, Number of adverse events (graded according to CTCAE v5.0 criteria) by epidiferphane dose level, ""Concentration at 24 hours (C24 hours) of Epidiferphanes components"", Concentration at 24 hours (C24 hours) of taxanes",
567,348455,,41,Functional Assessment of Cancer Therapy - Breast Symptom Index (FACT-B),
568,Vitamin D and breast cancer,,40,Osteocalcin,
569,LR19/011/50551,,558,Knowledge of alcohol as a breast cancer risk factor,
570,CTO-IUSCCC-0803,,200,Examine whether knowledge of ctDNA negativity influences patient decision-making,
571,Zz123456.,,100,"Change of EORTC QLQ-C30 Quality of Life Scale and QLQ-BR23 Module score at baseline and one week later after first, second, third and fourth chemotherapy., Change of Memorial Symptom Assesment Scale score at baseline and one week later after first, second, third and fourth chemotherapy., Change of Multidimensional Scale of Perceived Social Support score at baseline and one week later after first, second, third and fourth chemotherapy., Change of Beck Anxiety Inventory scale score at baseline and one week later after first, second, third and fourth chemotherapy.",
572,GBG102 - SASCIA,,1332,Invasive disease free survival (iDFS) between patients treated with sacituzumab govitecan vs. treatment of physicians choice.,
573,SYSKY-2022-030-01,,335,1.To assess the distribution characteristics of mHRR/HRD in breast cancer with low HRE2 expression in Chinese population,
574,KX-ORAX-CN-007,,24,"Cmax, Cmin, Cavg, AUC0-t, AUC",
575,PROICM 2018-05 BCU,,106,Sexual quality of life: EORTC SHQ-C22 questionnaire,
576,18-010602,,461,Breast Cancer,
577,CCH-IRB-190414-P,,180,"Operation time, Morbidity and complications, Nipple areolar complex ischemia/necrosis grading, Surgical margin involvement, Aesthetic outcome evaluation-Patient reported cosmetic outcome results, Blood loss during operations, Hospital stay, Resection mastectomy weight, Reconstruction implant volume, Pain assessments",
578,CLEE011O12301C,,5101,Invasive Disease-Free Survival,
579,BREAST-SK-001,,28,Objective response rates,
580,UI-ROD-OCTU02,,42,"Number of participants achieving pathological complete response (pCR) at surgery following neoadjuvant treatment with epirubicin + cyclophosphamide every three weeks for four cycles followed by paclitaxel + carboplatin every three weeks for four cycles, Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0",
581,HIRSLANDEN 01 SAKK 23/18,,420,Sensitivity,
582,CAAE: 91570318.5.0000.5149,,100,Impact in Quality of Life during pharmacological treatments,
583,18-641,,30,"Frequency of logging into the portal., Time spent in the portal., Time spent responding the survey., Frequency of information downloads., Participant-reported utility of the portal., Participant-reported recommendations for improving the portal.",
584,FWA00015574/6-01-2019/korany,,250,"The radiologic response rate, Overall survival (OS), Progression-free survival",
585,SOLTI-2101,,456,Progression-free survival,
586,PN-301-21,,146,2-year invasive disease free survival rate (iDFS),
587,KY20182079-F-1,,300,Detection of cell viability,
588,KY20202075-F-2,,30,pCR( pathological complete remission),
589,GIM21 - LiqERBcept,,48,"Number of index mutations, Rate of response/anticipation of relapse, Number of de novo mutations",
590,4-2018-0160,,200,"Change of patient reported psychosocial functioning score, Change of patient reported psychosocial functioning score, Change of patient reported patient treatment satisfaction score, Change of patient reported patient treatment satisfaction score, Change of patient reported physical functioning score, Change of patient reported physical functioning score, Change of patient reported body image score, Change of patient reported body image score, Change of breast cosmesis measures (excellent/good/poor), Change of breast cosmesis measures (excellent/good/poor), Change of breast-tissue fibrosis measures (gram), Change of breast-tissue fibrosis measures (gram)",
591,SOLTI-1805,,80,CelTIL score,
592,ROCK,,25,"Rate of acute skin toxicity events, measured according to RTOG/EORTC scale",
593,Radiation in breast cancer,,50,Disease free survival,
594,iOM-110383,"Study approved with treatment regimen based on current guidelines. However, reimbursement of IMP was not feasible.",0,Patient-reported health-related quality of life (QoL): FACT-B,
595,06805118.2.1001.5404,,800,Disease free survival (DFS),
596,ID4060,,52,"Objective responce rate, Time-to-treatment discontinuation",
597,MedOPP293,,393,"3-year recurrence-free interval (3y-RFI), Global health status decline, Global health status decline QoL, Global health status decline QLQ-BR23",
598,IRST174.25,,68,Treatment related toxicity,
599,AN.MCME.CR.12,,25,"Progression Free Survival, Overall Response Rate (ORR)",
600,EUROPA,,926,"Patient reported outcome measures (PROM) HRQoL as assessed by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30, Time to ipsilateral breast tumor recurrence (IBTR)",
601,UF-BRE-007,,74,"Cmax of Epidiferphanes components"", Cmax of taxanes, ""Concentration at 24 hours (C24 hours) of Epidiferphanes components"", Concentration at 24 hours (C24 hours) of taxanes, Maximum tolerated dose of Epidiferphane in patients with breast cancer who are being treated with taxanes, Rate of Common Terminology Criteria for Adverse Events (CTCAE) v5.0 grade 2 or higher neuropathy, Rate of Common Terminology Criteria for Adverse Events (CTCAE) v5.0 grade 1 or higher anemia",
602,0023041/i,,200,Radiomic of breast cancers and liquid biopsy,
603,2017-0499,,24,"Recommended phase II dose (RP2D) of M7824 and radiation therapy in patients with metastatic HR+/HER2- breast cancer, Safety and tolerability in patients with metastatic HR+/HER2- breast cancer",
604,HM022BC3C01,,339,Median progression-free survivalï¼mPFSï¼based on Independent Review Committee (IRC) assessment according to RECIST v1.1,
605,CASE13119,,100,"Beta-D-Glucagon levels, Short-chain fatty acid levels, Free amino acid levels",
606,SOLTI-2103,,120,Rate of pCRBL (ypT0/is ypN0) at surgery,
607,2020_61,,65,variation of score FSFI (female sexual function index),
608,SOLTI-1503,,28,Rate of residual cancer burden class 0 and 1 (RCB0/1),
609,UPCC 17120,,22,"Determine feasibility and Acceptability Using the City of Hope Quality of Life Instrument - Breast Cancer Patient to Assess Changes in Quality of Life, Determine feasibility and Acceptability Using the International Physical Activity Questionnaire to Assess Changes in Physical Activity, Determine feasibility and Acceptability Using the Patient Health Questionnaire to Assess Changes in Measures of Depression, Using the Acceptability of Intervention Measure to Assess Acceptability and Feasibility, Requesting Direct Verbal Feedback From Participants to Assess Elements of the Program that Work Well, to Acquire Suggestions, and to Seek Suggestions to Determine Feasibility and Acceptability",
610,LQ009,,500,5-year invasive disease-free survival (IDFS) rate,
611,IRB-57723,,25,Baseline levels of ctDNA detection,
612,BGB-900-2001-IIT,,96,"Overall Response Rate (ORR) by Investigator in Cohort A, Cohort B and Cohort C, Number of participants experiencing â¥ Grade 3 TRAEs in Cohort B",
613,115858,Surgery wait times during the COVID-19 pandemic were eventually reduced to pre-pandemic wait times. This study became irrelevant.,0,"Pathologic complete response (pCR), Feasibility of SBRT during a pandemic",
614,CLEE011H2301,Withdrawn due to change in plan for this study and not due to safety reasons.,0,Invasive disease-free survival (iDFS) using STEEP criteria,
615,D8530C00006,,10,"The number of subjects with dose-limiting toxicity, as defined in the protocol., The number of subjects with treatment-related adverse events as assessed by CTCAE v5.0.",
616,Shengjing_002,,420,Progression-free survival,
617,IIT-UM2018001,,44,Overall response rate (ORR),
618,ONAWA (SOLTI-1802),,10,Complete Cell Cycle Arrest (CCCA),
619,Shengjing-LJY04,,500,Disease-free survival,
620,1,,120,Assess the G3 toxicity rate,
621,ZX-2021-FES-ESTROTIMP-4,,152,"To assess the impact of ESTROTEP PET/CT on metastatic breast cancer patients management, initially ER+ and HER2-, in relapse after first-line treatment combining hormone therapy.",
622,CCH-IRB-190414-R,,900,"Operation time, Wound healing status, Skin blister formation, Skin flap ischemia/necrosis rate, Implant loss rate, Post operation Bleeding/hematoma rate, Post operation Bleeding/hematoma rate, Seroma formation rate, Grade of Nipple areolar complex ischemia/necrosis, Rate of Surgical margin involvement in specimen pathologic examination, Aesthetic outcome evaluation-Patient reported cosmetic outcome results, Blood loss during operation, Hospital stay, Mean mastectomy weight, Reconstruction implant volume",
623,STUDY00010776,,24,Brief Pain Inventory (Modified for Joint Pain),
624,3764,,30,Technical feasibility of planning SBRT to multiple sites,
625,2019-004559-35,,27,To estimate the loco-regional invasive disease-free survival of patients who achieve a complete response,
626,UCCS20110,,10,Functional Assessment of the Discussion Prioritization Tool (DPT),
627,RP-20-013,Limited staff to carry out study,0,Tumor progression,
628,KARMA Kontrast,,420,Sensitivity of Contrast Enhanced Mammography,
629,STUDY2019000317,,1000,Disease Recurrence,
630,STUDY00001225,,452,"Change in depression features, Change in anxiety features",
631,BREAST,,300,Progression-free survival (PFS),
632,2020-535,,332,False negative rate (FNR) of targeted axillary lymph node resection,
633,ACE-Breast-03,,31,Objective response rate (ORR),
634,FirstHCMU_CB_001,,1354,"Disease-free survival up to 16 years, Invasive disease-free survival up to 16 years, Distant disease-free survival up to 16 years",
635,CCR5119,,184,Complete tumour response 12 months post-radiotherapy assessed by MR,
636,FMBSUREC/10102021/Rabie,,60,"Ki-67 molecular, TAZ (WWTR1) TAZ expression, cardiac markers",
637,GEICAM/2017-04,,32,"Genomic alterations on tumor samples with Objective Response (OR) to Kadcyla, Tumor-specific mutation in plasma samples with OR to Kadcyla",
638,dAGEs,,32,"Dietary Advanced Glycation End Products Intake (kilounit/day), Serum carboxy methyl lysine (CML) level (pg/mL), Serum receptor for advanced glycation end products (RAGE) level (pg/mL), Serum soluable receptor for advanced glycation end products (sRAGE) level (pg/mL), Serum tumor necrosis factor alfa (TNF-Î±) level (pg/mL), Serum interleukin 1 beta (IL-1Î²) level (pg/mL), Serum interleukin 6 (IL-6) level (pg/mL), Serum lipid peroxidation level: Malondialdehyde (nmol/mL), Serum protein oxidation level:2,4-Dinitrophenylhydrazine (nmol/mL), Serum DNA damage level: 8-hydroxy 2 deoxyguanosine(ng/mL), Serum total antioxidant capacity (Î¼mol/L), Dietary total antioxidant capacity: Total Oxygen Radical Absorbans Capacity (T-ORAC) (Âµmol Trolox equivalent), Dietary total antioxidant capacity: Lipophilic Oxygen Radical Absorption Capacity (L-ORAC)(Âµmol Trolox equivalent), Dietary total antioxidant capacity: Hydrophilic Oxygen Radical Absorption Capacity (L-ORAC)(Âµmol Trolox equivalent), Dietary total antioxidant capacity:Trolox Equivalent Antioxidant Capacity (TEAC) (mmol Trolox equivalent), Dietary total antioxidant capacity:Total Radical Trapping Antioxidant Parameter (TRAP) (mmol Trolox equivalent), Dietary total antioxidant capacity:Ferric Reducing Antioxidant Potential (FRAP)(mmol), Dietary inflammatory index (score), Nutritional status",
639,21-271,,30,Baseline VO2peak in participants with HER2-positive breast cancer,
640,1808-42,,103,Change in level of self-reported financial burden,
641,3475-756,,1240,"Pathological Complete Response (pCR) Rate Using the Definition of ypT0/Tis ypN0, Event-Free Survival (EFS)",
642,2022-0055,,1576,pCR(pathological complete response),
643,WEFITTER,,68,"Assess quality of life through the quality-of-life questionnaire through the Functional Assessment of Cancer Therapy - Breast, Assess quality of life through the quality-of-life questionnaire through the Functional Assessment of Cancer Therapy - Breast, Assess quality of life through the quality-of-life questionnaire through the Functional Assessment of Cancer Therapy - Breast, Assess quality of life through the quality-of-life questionnaire through the Functional Assessment of Cancer Therapy - Breast",
644,A5481178,,1,Number of Participants With HR+/HER2-ABC/MBC receiving palbociclib combination treatment,
645,ARO-2015-1,,564,"First co-primary outcome measure is progression-free survival (PFS), Second co-primary outcome measure is quality of life",
646,20-124,,400,Vaginal dryness,
647,DKFZ-2019-008,,240,Invasive Disease-free Survival (IDFS) as defined by Hudis et al in the entire study population four years after surgery,
648,EF141,Strategic changes regarding the product development,0,Duration of severe neutropenia (grade 4) in days during chemotherapy cycle 1.,
649,SHPD005,,196,"Residual cancer burden (RCB 0-I ratesï¼, Pathologic Complete Response (pCR) of the Primary Tumor in the Breast",
650,20170328,,31,The pathological complete response (pCR) rate in the breast and lymph nodes (ypTis/0ypN0),
651,HNCH-MBC11,,71,Objective response rate (ORR),
652,NIR-THERMA-02,,459,"Sensitivity, specificity, positive predictive value and negative predictive value of Thermalytix",
653,Pro00020138,,28,MTD,
654,SOLTI-1507,,25,To define the Recommended Phase 2 Dose (RP2D) of ipatasertib when used in combination with HP (+/- ET),
655,E7389-M082-602,,340,Progression-free survival (PFS) rate at 6 months,
656,18-394,,100,Adjuvant chemotherapy Received,
657,LaPemERLA,,40,Objective Response Rate (ORR),
658,123123,,196,Change from baseline in fatigue over the whole intervention,
659,2019SABE028,,42,"determination of limb volume changes, determination of shoulder and upper extremity functions, muscle shortness test, Bioimpedance analysis for body composition determination; weight, Bioimpedance analysis for body composition determination;body mass index, Bioimpedance analysis for body composition determination; body fat and water percentage, Bioimpedance analysis for body composition determination; visceral fat level, Bioimpedance analysis for body composition determination; energy consumption, Bioimpedance analysis for body composition determination; metabolic age, determination of subdermal fluid ratio, assesment of fatigue, determination of cardiovascular endurance",
660,IIBSP-PRO-2021-10,,64,"Disabilities of the Arm Shoulder and Hand Questionnaire (Quick DASH), Disabilities of the Arm Shoulder and Hand Questionnaire (Quick DASH), Disabilities of the Arm Shoulder and Hand Questionnaire (Quick DASH), Disabilities of the Arm Shoulder and Hand Questionnaire (Quick DASH)",
661,2021/193780(REK),,100,"To study the change in levels of direct and indirect immunologic biomarkers of targeted cancer therapy with letrozole and ribociclib given in combination for patients with locally-advanced, ER-positive, HER-2 negative, luminal A7B breast cancer",
662,CP7-005,,170,"Soluble Tumor Necrosis Factor Receptor (sTNFR) concentrations in plasma (picogram per mL), Safety and Tolerability Assessment, Safety endpoints of special interest assessment, Clinical endpoint - overall survival, Clinical endpoint - progression free survival, Clinical endpoint - disease control rate",
663,STUDY00001233,,700,Sensitivity and specificity of ThermalytixTM in detecting breast cancer,
664,SYSUCC-015,,520,disease-free survival (DFS),
665,INCASE0518,,150,Quality of Patient information,
666,CIMS-4FMFES-2021-3966,,150,"Correlation of 4FMFES-PET uptake with histopathological markers, notably ER immunohistochemistry (IHC) score, Evaluation of progression-free survival versus 4FMFES-PET uptake threshold, Evaluation of time-to-recurrence versus 4FMFES-PET uptake threshold, Correlation of treatment response with reduction of 4FMFES-PET uptake and number of assessable lesions at 6 and 18 months after the initial assessment, Complementarity analysis of FDG-PET with 4FMFES-PET",
667,2019.429,,122,"Change from baseline self-esteem at 2 months,The Rosenberg Self-esteem Scale (RSES)",
668,REO 026-1,,15,Number of participants with Dose Limiting Toxicities (DLTs),
669,HLX11-BC301,,900,The total pathological complete response (tpCR) rate assessed by the Independent Review Committee (IRC),
670,JTU-6H-20211011001,,288,"Incidence of lymphedema, Incidence of dysfunction",
671,Stage 2 compression therapy,,72,Arm volume,
672,INST 1607,,30,Assess the correlation of serial high-speed MRSI of [tCho] with pCR following NAC,
673,Yunwei Wei 2019-09-13,,80,Transcriptional changes in gut microbiota,
674,SOLTI-1718,premature termination due to lack of funding,12,Progression-Free survival PFS6 (Efficacy),
675,Tacrolimus_2020,,20,Change in Arm volume from Baseline,
676,CL1-81694-003,,22,"Incidence of DLTs (dose-limiting toxicities), Safety and tolerability assessed by incidence of Adverse Events, Abnormalities in laboratory tests (haematology, blood biochemistry and urinalysis), Abnormalities in physical examination and performance status (ECG) (mm/s), Abnormalities in blood pressure (mmHg), Abnormalities in heart rate (BPM (beat per minute)), Abnormalities in body temperature (CÂ°degree celsius), Abnormalities in respiration rate (cycles per minute), Abnormalities in body weight (Kg), Progression free survival (PFS) [based on Investigator review of the images according to RECIST 1.1]",
677,PROICM 2020-07 VIS,,25,Patient adherence of a coaching program for an adapted return to work,
678,Zoledronic Acid In Breast Ca,,50,The percentage change in lumber spine (L2-L4) BMD at 12 and 24 months for immediate- versus delayed-ZOL patients.,
679,CASE5120,,72,"Functional Assessment of Cancer Therapy: Breast Cancer (FACT-B) questionnaire scores, FACT-B questionnaire scores, FACT-B questionnaire scores, FACT-B questionnaire scores",
680,2020.KB.SAG.069,,60,"Change in Breast Cancer Related Lymphedema Self-Care Scale Score, Change in Quality of Life Measure for Limb Lymphedema-Arm Scale Score, Change in Lymphedema Symptom Intensity and Distress Survey Score",
681,6788,,100,Presence or absence of of pathologic enhancement of breast by MRI,
682,KSRAD001,,2500,Significantly Delayed Breast Cancer Detection per 1000 women,
683,20-157,,120,"Tumor Infiltrating Lymphocytes (TILs; CD3+/CD8+ T-cell Breast Immunoscore), Rate of pathologic response in the lymph node",
684,INNOVBC,,128,"Depression, Anxiety",
685,NCC1824,,200,"The study was designed to investigate the relationship between plasma HER2 amplification or specific mutations abundance and imaging assessment in patients with recurrent or metastatic breast cancer., The study was designed to investigate the proportion of predicting in advance the treatment efficacy of recurrent or metastatic breast cancer by plasma HER2 ctDNA.",
686,Shengjing-LCG005,,110,Pathologic complete remission rate,
687,WO39391,,2300,Invasive Disease-Free Survival (iDFS),
688,HunanCH-BC-001,,100,Total pathologic complete responseï¼tPCRï¼,
689,GENEXAN,,100,"Whole genome expression by microarray, Whole genome expression by mircoarray",
690,2-102-21,,120,"Amount of lipid composition in the breast, Spatial distribution (skewness) of lipid composition in the breast, Spatial distribution (entropy) of lipid composition in the breast, Spatial distribution (kurtosis) of lipid composition in the breast",
691,GRO-06-001,,675,Diagnostic performances of ABUS and HHUS,
692,R20-003,,20,Measure neuroinflammation by calculating the concentration and regional distribution of activated brain microglia/macrophages using PET ligand [F-18]DPA-714.,
693,DS8201-A-U305,,1600,Invasive Disease-free Survival (IDFS) in Participants Who Were Administered Trastuzumab Deruxtecan (T-DXd) Compared With Trastuzumab Emtansine (T-DM1) Treatment,
694,2021.693,,126,Change in self-efficacy,
695,HSC20160245H,,108,Change in Adherence to EHT,
696,MedOPP319,,80,Progression-free survival (PFS),
697,NCC1867,,300,Psychological Distress Thermometer(DT),
698,2000025837,,6,"Objective response rate (ORR), Safety profile",
699,Shengjing_001,,120,Pathologic complete response time,
700,16D.674,,200,Tumor biomarker identification,
701,REC-H-PHBSU-21010,,100,"Overall survival (OS) after treatment of Tocilizumab, progression free survival (PFS), time of improvement or worsening at least one point change in ordinal scale",
702,PREDIX II HER2,Security and effect data from another ongoing study.,6,Rate of pathological objective response to primary medical treatment,
703,Melody_002,,1500,Accuracy Measure,
704,Neveen,,100,The survival rate of breast cancer in assiut university hospital,
705,PCS-001,,450,Concordance between liquid and tissue biopsy in terms of presence or absence of cancer,
706,YOUNGBC-22,,72,Progression-Free Survival (PFS),
707,2018.016,,164,Liquid-biopsy in monitoring treatment response in luminal breast cancer,
708,18-603,,100,Feasibility and Acceptability,
709,R.20.05.834,,120,Clinical Response rate,
710,17/209,,31082,"Compare rates of screen detected breast cancer after subsequent screening with DBT+SM after DBT+SM versus screening with DBT+SM after prior DM, as performed in a population based screening program.",
711,ATADEK 2022-17/27,,38,"Muscle strength, Range of motion",
712,SMC-2019-05-021 (2),,100,Range of motion in affected shoulder,
713,2018.08.ST,Relocation of Principal Investigator,7,Number of Participants With Progression-free Survival at 12 Months Based Upon Clinical and Radiological Assessments Completed as Part of Routine Care,"Death, Premature Termination of Study"
714,2020/33,,40,early toxicities occuring until 6 months after performing per-operative radiotherapy,
715,HE071-CSP-021,,73,Objective response rate (ORR),
716,2021-0170,,190,disease free survival,
717,SMC- 5725-18,,200,To evaluate the efficacy of a personalized diet compared to a standard low fat diet to control body mass as measured by changes in body mass.,
718,ORIN1001-001,,150,"To determine the safety of MTD/RP2D of single-agent daily ORIN1001 when administered orally in subjects with advanced solid tumors: NCI CTCAEv5 Common Toxicity Criteria, To determine the safety MTD/RP2D of daily ORIN1001 when administered orally in combination with paclitaxel given intravenously at 175 mg/m2 once every three weeks in subjects with relapsed refractory metastatic breast cancer, To evaluate the safety and tolerability of single-agent daily ORIN1001 when administered orally in the dose escalation and expansion stages of the study: NCI CTCAEv5 Common Toxicity Criteria, To evaluate the safety and tolerability of daily ORIN1001 when administered orally in combination with Abraxane given intravenously at 100 mg/m2 once weekly for 3 weeks in the dose escalation and expansion stages of the study",
719,CHIR-01-sentinel,,61,Clear indications for SLNB or axillary dissection,
720,D3615C00001,,818,Progression-Free Survival (PFS) in the overall population and in the PIK3CA/AKT1/PTEN-altered subgroup,
721,MCC-20902,,13,Recommended Phase 2 Dose (RP2D),
722,1563/2018,,108,"Pain classification change, Arm strength change, Change in the amplitude of arm movement, Upper limb disability change",
723,YYS-20200305,,80,Progression-Free Survival,
724,HNCH-BC010,,456,Pathological Complete Response (pCR),
725,PUMCH-SBSBC,,314,DFS,
726,PUMCH-BC501,,200,"immune inflammation-related protein complexes, blood markers",
727,Breast Cancer-RISS,,50,Postoperative opiod consumption,
728,MACSSI (ET18-150),,40,"To characterise quantitatively and qualitatively, after solitary confinement, the resident breast stem cells and the immune system cells infiltrated in the mammary gland according to the risk of breast cancer progression (group A and B)",
729,B27IB3856,,30,High-sensitivity C-Reactive Protein (CRP),
730,C3441053,,110,Time-to-treatment failure for talazoparib for primary population,
731,CAN04CLIN005,,116,"Incidence rate of Dose Limiting Toxicity (DLT) within the first cycle of nadunolimab in combination with gemcitabine plus carboplatin, Objective Response Rate (ORR)",
732,LCCC2105,,15,Qualitative Summaries of Interviews about Participant Experience with Telemedicine,
733,"2016-051-000001, 2563",,3000,Prevalence of women who have made the decision about screening participation prior to screening invitation.,
734,YOUNGBC-7,,19,Staging of breast cancer,
735,LUN_MMG_121,,240,Patient-level FBR (forced BI-RADS) area under the Receiver Operating Characteristic (ROC) curve,
736,STML-ELA-0322,,80,Progression-free survival rate,
737,H-50349,,185,Change in Clinical Tumor Measurement vs. Pathologic Response,
738,MIES-BCNAT,,300,"Quantitative analysis parameters and cut-off values of contrast-enhanced ultrasound prediction and early evaluation of NAT efficacy;, Enhanced MRI prediction and DWI for early evaluation of NAT efficacy, and enhanced quantitative analysis parameters and cut-off values, Able to predict and assess the stage of axillary lymph nodes after NAT and guide the development of diagnostic criteria for treatment strategies, Construct a multi-modal and multi-parameter evaluation system and its standards that can predict and early evaluate the efficacy of NAT.",
739,NCC2019-0142,,5000,"local and regional lymphnode control, free-recurrence, survival period",
740,20G.605,,25,Correlation between subharmonic aided pressure estimation (SHAPE) results and direct measurements of interstitial fluid pressure (IFP),
741,RJrapidplan,,195,â¥Grade 2 acute radiation-induced toxicity,
742,NIS12501,,130,"Description of age, Description of Gender, Description of BMI, Menopausal status, Comorbidities, HER2 overexpression/amplification testing, Hormone receptor status, Primary tumor location, Primary tumor histology, Histological grade, Pathologic stage (AJCC classification) of Breast Cancer",
743,eMOUVOIR-1901,,1133,"Quality of Life (QoL): SF 36 PCS, Quality of Life (QoL): SF 36 MCS",
744,LACUDY,,60,Change of Vaginal health index,
745,2-049-18,,12,"Cardiac Energetics, Cardiac Energetics",
746,UT BCS Sleep Study,Due to COVID this study was never started.,0,Change in Sleep Quality (Pittsburgh Sleep Quality Index),
747,22SCH740,,36,Clinical Benefit Rate,
748,B002-101,,23,"Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT)",
749,19-002792,,20,"Increase in skin quality, Physical Well-Being Using the BREAST-Q Reconstruction Module, Effects of skin disease on quality of life, Skin Toxicity Costs",
750,919PP17,,100,"Troponin-T in ng/l, Vitamin D in ng/ml, LDH in U/L, Interleukin-6 in MIU/ml",
751,MCC-21378,,28,Maximum Tolerated Dose (MTD) of expanded CD4 T cells,
752,2022-7735,,120,Change from baseline Post-traumatic growth (PTG) assessed by the Post-Traumatic Growth Inventory (PTGI),
753,2021-0358,,20,To determine the efficacy of zanidatamab for patients with early stage HER2/neu positive (HER2+) breast cancer (BC) as determined by pathologic complete response (pCR,
754,20210504,,200,Sensitivity,
755,010006,,9,"Blood Clearance, Excretion, Biodistribution, SPECT/CT imaging, Distributed in organs",
756,UC-0105/1815,,186,Antitumor activity of DS-8201a in the 3 cohorts of patients,
757,18-2444.cc,,35,Percentage of compliance in each of the 4 assessment tools,
758,NCC3340,,26,"Pathological complete response (pCR) rate using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) at the time of definitive surgery",
759,YOMA,,138,Functional Assessment of Cancer Therapy - Breast Cancer (FACT-B),
760,C4891023,,35,"Phase 1b: Number of Participants With Dose Limiting Toxicities, Phase 2: Percentage of Participants With Objective Response by investigator assessment",
761,CSPC-DMS-BC-17,,40,Pathological complete response(pCR) rate,
762,GS-US-595-6184,,1514,Invasive Disease-free Survival (iDFS),
763,SYSU-2022-02,,28,"Pathology tpCR (ypT0/is, ypN0) rate",
764,HR-BLTN-008,,86,Clinical Benefit rate (CBR),
765,HR BLTN 014,,41,ORR,
766,IRB00130428,,30,"Change in percent expression of Ki67 measured by immunohistochemistry (IHC), Change in percent expression of Ki67 measured by single-gene read out",
767,GO40987,,75,"Change From Baseline in Tumor Cell Proliferation, as Measured by the Proportion of Nuclei Staining Ki67-Positive at Surgery Relative to Baseline in Pre- and Post-Treatment Tumor Biopsy Samples, Change From Baseline in Tumor Cell Proliferation, as Measured by the Difference in the Percentage of Nuclei Staining Ki67-Positive at Surgery Compared With Baseline in Pre- and Post-Treatment Tumor Biopsy Samples",Withdrawal by Subject
768,HNCH-MBC08-BM02,,100,CNS-ORR according to the RECIST 1.1.,
769,19-003532,,400,"Changes in the ctDNA detection rate in mutational load in breast cancer patients with indications of regional nodal irradiation., The change in the proportion of patients with detectable ctDNA at the end of treatment and 3 months compared to baseline., The correlation of detectible ctDNA at each time point with invasive recurrence-free survival",
770,TRICIA,,130,Develop signatures of good and poor outcome as well of tumor response to chemotherapy in TNBCs by integrating multidimensional profiling of both tumor and liquid biopsies making use of Artificial Intelligence (AI) tools,
771,1780,,150,"Localisation of pain, Pain intensity, Influence of pain on the quality of life, Severity of pain symptoms",
772,STU00206180,,84,"Change in Self Reported Adherence to Hormone Therapy will be evaluated with the ARMS questionnaire., Change in Health Related Quality of Life will be evaluated with The Functional Assessment of Cancer Therapy-Endocrine (FACT-ES), Electronically Verified Hormone Therapy Adherence will be measured using medication event monitoring systems (MEMS), Pharmacy reported Adherence to Hormone Therapy will be measured using pharmacological records",
773,MA-BC-II-006,,20,"pCR rate using the definition of ypT0/Tis ypN0 (i.e., no invasive residual in breast or nodes; noninvasive breast residuals allowed) at the time of definitive surgery",
774,HR-TNBC-HN100,,39,Pathological Complete Response (pCR),
775,SNF4,,145,PFS,
776,PALBOCOMP,,237,Time to progression,
777,17/013,,54,Progression Free Survival,
778,2020 - 176,,60,"clinical response rate, Relative reduction of Ki67 in tumor samples",
779,OkanU2,,120,Better survival,
780,LACOG 0221,,300,The proportion of type of first-line treatment,
781,SNF3,,200,PFS,
782,EC/TMC/108/17,,30,Toxicity (CTCAE v 4.03),
783,2019-09-09,,120,Identification rate of sentinel lymph node,
784,2018-68-1461,,1560,disease free survival,
785,YANWQ002,,100,Comparative assessment between risk groups,
786,SGRT-BC,,556,"Accuracy of treatment location, Incidence of patient coronary events/myocardial perfusion decline",
787,MR-01,,80,Complete Pathologic Response (pCR),
788,PALBOSPAIN,,815,Real-world progression free survival (rwPFS),
789,CMUH108-REC3-090,,10,The change of scores of study questionnaire between baseline and each time point used to evaluate the breast cosmetic domain and specific breast pain domain.,
790,UBRS20013,,20,One Year Invasive Disease-Free Survival,
791,HR-BLTN-014,,20,Objective Response Rate,
792,EBaran,,30,"Touching sensation, Two-point discrimination, Pressure pain threshold",
793,SPI-POZ-101,Dose limiting toxicity,6,Objective Response Rate (ORR),
794,OstacoliMIND&BC,,100,"changes in depression symptoms, changes in depression and anxiety symptoms, changes in HRV",
795,2019-0088,"Due to insurance non-payment, no subjects were enrolled.",0,"Cosmetic outcome (change in appearance as compared to untreated breast), Cosmetic outcome (change in appearance as compared to untreated breast)",
796,261\\2021,,150,Comparison of frequency and severity of symptoms using real-time tele-monitoring versus routine symptom monitoring.,
797,RC48-C012,,366,"Progression-free survival (PFS), evaluated by an independent efficacy evaluation committee",
798,R20-030,,25,"Baseline measure of PET standardized uptake value (SUV)., Baseline measure of apparent diffusion coefficient (ADC) in mm2/sec from MRI., Baseline measure of signal enhancement ratio (SER) from MRI., Changes in SER from MRI, Changes in ADC from MRI, Changes in SUV from PET",
799,SYSA1901-002,,560,Total pathologic complete response (tpCR) assessed by Independent Review Committeeï¼IRCï¼,
800,OTT 18-02,,262,Endocrine toxicity,
801,CYH33-G103,,228,Dose Limiting Toxicities (DLT),
802,ERIBRAIN-IPC 2017-014,no enrollment,0,Efficacy of eribulin for treatment of HER2-negative BCBM,
803,2019/2452,,70,"Change in participants health-related quality of life"", ""Change in participants physical and psychological symptom distress levels",
804,CMUH106-REC3-137,,54,Acupuncture can improve joint symptoms resulting from aromatase inhibitor and quality of life,
805,NL77000.029.21,,100,Pathologic complete response,
806,HR-BLTN-010,,60,Objective Overall Response Rate (ORR),
807,MUKDEN 07,,61,Total pathological complete response (tpCR: ypT0-is/ypN0),
808,NCC3286,,64,Objective Response Rateï¼ORRï¼,
809,YBCSG-21-03,,92,PFS,
810,20-104,,31,System Usability Scale (SUS) score,
811,99mTc-ADAPT6,,16,"Gamma camera-based whole-body 99mTc-ADAPT6 uptake value (%), SPECT-based 99mTc-ADAPT6 uptake value in tumor lesions (kcounts), SPECT-based 99mTc-ADAPT6 background uptake value (kcounts), Tumor-to-background ratio (SPECT)",
812,STUDY00022698,,1141,"Uptake of MammoScreen, Number of women with above-average risk for breast cancer identified by MammoScreen integrated with the electronic health record (EHR)",
813,SMX 22-002,,400,Progression free survival (PFS),
814,SCAN-B-rec,,2000,Survival,
815,DS8201-A-U303,,557,Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR),
816,20F.259,,200,Prediction of the patients clinical and pathological response,
817,9745,,256,Abnormal interpretation rate,
818,LMengmeng,,244,Fear of cancer recurrence,
819,2010134480,,100,Global Costs,
820,SLNB-ACP,,100,"Impact of sentinel lymph node biopsy procedure on locoregional recurrence for group 3 sentinel node negative patients, Correlation of sentinel node negative patients from group 3 patients and overall survival, Correlation of sentinel node negative patients from group 3 and disease progression free survival",
821,NCC1888,,68,objective response rate(ORR),
822,H18-02581,,50,"Feasibility of neoajduvant Ki-67 and Oncotype DX, defined as >=75% enrollment rate for all screened patients, Turnaround time of Ki-67 and Oncotype DX, defined as time from patient consent to date results are obtained, Feasibility of MRI prior to neoadjuvant systemic treatment, defined as >=75% of patients who receive an MRI before the start of neoadjuvant treatment, Turnaround time of MRI prior to neoadjuvant systemic treatment, defined as time from patient consent to date of 1st MRI",
823,J1836,,33,Clinical Complete Response,
824,K171005J,,186,Multidimensional Measure of Informed Choice (MMIC),
825,X-XJTU1AFLSY-93,,209,PFS,
826,HCI131027,,15,Number of cases where clinically actionable outcomes were identified by the use of organoids and drug screening (functional precision oncology).,
827,D967JC00001,,245,"Occurrence of adverse events (AEs)- Part 1, Occurrence of serious adverse events (SAEs)- Part 1, Occurrence of adverse events (AEs)- Part 2, Occurrence of serious adverse events (SAEs)- Part 2",
828,18-371,,80,Change from baseline in mean weekly HFS score between acupuncture and usual care arms at the end of week 10,
829,AI-BMRI,,5000,screening yield,
830,SCHBCC-N030,,356,iDFS,
831,CLEE011AUS64,,4650,"Number of participants with a prescription fill of ribociclib, palbociclib, or abemaciclib, Number of participants who took concomitant medications in baseline period, by drug name, Number of participants who took concomitant medications in follow-up period, by drug name, Number of participants with no use of concomitant medications, Number of participants with proportion of days covered (PDC) >80%, Number of participants with proportion of days covered (PDC) â¤80%, Number of other breast cancer medications used",
832,ERC/2020/10/11 (26/10/2020),,4100,"Participation rate, Abnormal call rate, Breast cancer detection rate, Stage at presentation, Timeline from presentation to treatment, Retention rate",
833,19-055,,20,Maximum Tolerated Dose,
834,BC-P29,,136,ipsilateral axillary recurrence-free survival,
835,2021/32,,70,Ontological Well Being Scale,
836,XZP-3287-3002,,372,Investigator-assessed progression free survival (PFS),
837,R21-072,,20,"Baseline measure of PET standardized uptake value (SUV)., Baseline measure of apparent diffusion coefficient (ADC) in mm2/sec from MRI.",
838,SCHBCC-N025,,46,ORR,
839,OMICS Mark,,500,Metabolites changes of plasma by High Performance Liquid Chromatography-Mass Spectrometry (LC-MS).,
840,Smart,,108,Change from baseline quality of life scores at 4 months,
841,RS-NAT01,,80,2-year DFS,
842,TeMP 2021,,130,"Neutrophil-lymphocyte ratio, Neutrophil-lymphocyte ratio",
843,MC220301,,100,Change in pregnancy-related breast cancer (PRBC) score,
844,BOMB,,183,Progression-free Survival (PFS),
845,SMX 20-001,,29,"Safety and tolerability of the combination of lasofoxifene and abemaciclib as measured by number of adverse events (AEs), severity of AEs and mortality due to AEs at every scheduled visit.",
846,2019/1318,,210,Change in VO2peak,
847,D931CC00001,,80,"To evaluate the efficacy, measured by pCR (pathological complete response) rate, of olaparib monotherapy and olaparib plus durvalumab combination therapy, as assessed by central pathology review.",
848,Stage 1 Compression Therapy,,72,Arm volume,
849,XuzhouMedSch3,,100,QoR40 score,
850,FUSCC-TNBC-BLIS,,192,PFS,
851,20-371,,62,"Tumor-infiltrating lymphocytes (TILs), The number and proportion of participants achieving Pathologic Complete Response (pCR)",
852,SMC 2018-07-014-011,,20,"total sleep time, walking steps and walking time",
853,2019-KY-051,,185,Percentage Change From Pre-treatment to Post-treatment in Ki-67 Labelling Index,
854,WuhanU,,20,pCR rate,
855,2022-017,,40,Studying the impact of chemotherapy combining EC and Tax on myocardial deformations (at rest and at submaximal effort) in order to identify the kinetic of systolic and diastolic dysfunctions.,
856,K3_K1_2,,88,"Change in the Functional Assessment of Cancer Therapy - Breast (FACT-B; Brady et al., 1997)",
857,HBMUFH-101,,300,Clinical/pathological response,
858,4298,,76,Insomnia Symptoms,
859,018-745,,10,Efficacy (objective response rate),
860,GEICAM/2018-03,,31,"Amount of innate immune cells, Activation level of innate immune cells, Analyses of the expression level of cytokines and/or rNKG2D ligands",
861,213355,,21,Percentage of Participants With Tumor Response Measured by Breast MRI,
862,GCX-BCT-06,,194,10-year distant metastasis free survival,
863,2022-0056,,2413,5-year DFS,
864,MEDOPP437,,28,"Cohort A: To assess the efficacy of MEN1611 in combination with eribulin as determined by the clinical benefit rate (CBR)., Cohort B: To assess the efficacy of MEN1611 as monotherapy defined as objective response rate (ORR).",
865,handan1,,200,Enrichment of circulating tumor cells,
866,20192755,,100,development of cardiovascular diseases and complications,
867,42127,,120,"DNA and mRNA sequencing, Duffy-antigen receptor for chemokines",
868,SYSKY-2023-129-01,,170,positive margin rate,
869,ACR A4707,,2032,"Cancer Detection Rate, Recall Rate",
870,PREBCA,,44,Brief pain inventory (BPI),
871,Melody_001,,205,Validation of Melody,
872,BC-P31,,420,The diagnostic performance of the blood assay for differentiating benign and malignant breast disease using glycosylated extracellular vesicles analysis,
873,UW20035,,15,PSMA Expression as measured by 18F-DCFPyL SUV,
874,D9670C00001,,850,"Progression Free Survival (PFS) - in HR+, HER2-low populaton",
875,2-025-19,,40,"Saturated fatty acids in breasts of patients and high-risk group, Monounsaturated fatty acids in breasts of patients and high-risk group, Polyunsaturated fatty acids in breasts of patients and high-risk group",
876,SaglikBilimleriU_DU,,52,Symptom management,
877,20-09022641,,102,Progression free survival (PFS) will be measured,
878,R868/18-IEO 916,,660,"Change in Resilience, Personality, Dispositional optimism, Sense of coherence, Change in Post traumatic stress disorder, Change in Positive outcome after trauma exposure, Change in Coping flexibility, Change in Cognitive coping strategies, Change in Dispositional mindfulness, Change in Mental adjustment to cancer, Change in Social support, Change in Family resilience, Change in Illness representation, Change in patients Self-efficacy in coping with cancer, Change in Depression and anxiety, Change in Quality of life assessed by EORTC-QLQ C30, Change in Quality of life in patients with breast cancer assessed by EORTC-QLQ BR23, Change in Fear of cancer recurrence, Change in Positive and negative affect, Change in Distress",
879,EORTC-1550-BCG,,100,"Number of enrolled patients per year with adequate clinicopathologically annotated biological material and clinical data., Disease progression, Treatment resistance",
880,I3Y-NS-O003,,120,objective response rate (ORR) while being on study treatment using RECIST V1.1.,
881,OTT 20-11 (IT-02),,90,"The proportion of patients achieving a CCCA defined as a reduction in the proportion of cells staining positive for Ki67 as assessed by immunohistochemistry to less than a natural logarithm, or â¤2.7%, at the post-treatment specimen.",
882,IOM-120465,,300,"Time to deterioration of EORTC global health scale by at least 10 points, Changes in the global health scale",
883,OBU-SC-BB-BC-II-010,,216,Pathological complete response rate (pCR) (ypT0/is N0),
884,309424,,1000,"Mammographic Density and Risk, Psychological impact",
885,D9673R00025,,750,"Real-World Time to Next Treatment (rwTTNT), T-Dxd treatment patterns",
886,19-1812.cc,,200,Establishing distress level using questionnaires,
887,mTPVB SPPB Ver 2,,100,Proportion of patients requiring intraoperative ketamine,
888,SNB vs PET/MRI 1,,110,Axillary surgery vs PET/MRI.,
889,NIHR 128311,,1900,"Disease free survival (DFS), Patient reported lymphoedema",
890,2019-053,,142,Mammography receipt,
891,ID-TMS-02-20201012,,150,"Overall Survival rate, Progression Survival rate",
892,CABC012,,97,PFS of two regimen,
893,STUDY00000023,,24,Quantification of Grade 3 and 4 toxicities (Adverse Events),
894,20_RIPH3_06,,142,"Assessment of global disorders in patients with breast cancer, Assessment of disorders specific to breast cancer patients Assessment of disorders specific to breast cancer patients, Assessment of global disorders in patients with breast cancer, Assessment of disorders specific to breast cancer patients",
895,ACE-Breast-07,,54,Objective remission rate (ORR),
896,Pro00104868,,18,Number of Adverse Events,
897,GMI-1359-210,"After demonstrating the on target effect of GMI-1359 via pharmacodynamic markers (CXCR4 and E-selectin), Sponsor terminated the trial due to COVID-related slow enrollment.",4,"Occurrences of dose-limiting toxicities (DLT) including protocol-defined adverse events (AEs)/serious adverse events (SAEs), and/or laboratory abnormalities will be assessed in order to determine recommended phase II dose (Safety and Tolerability)",
898,2021C0128,,30,Evaluate feasibility through recruitment and retention,
899,MA-BC-II-023,,100,ki67 index,
900,ICO-A-2018-10,,140,To show the noninferiority of early early medical treatment by topical treatment with capsaicin compared to oral treatment of pregabalin on the evolution of neuropathic pain after 2 months in patients who have undergone surgical excision of breast cancer,
901,AITIC,,27000,"Assessment of Workload of each strategy, Assessment of Workload of each strategy, Detection rate, Detection rate, Recall or referral rate, Recall or referral rate",
902,RG_16-108,,150,Observed number of patients with false negative biopsies,
903,2022/0132,,48,"measurement of tissue stiffness (N/m), measurement of passive muscle tone (Hz), measurement of creep of tissue, measurement of the range of shoulder joint motion, assessment of activity of daily living, assessment of depression and anxiety",
904,0494-22-RMB,,30,"Rate of severe (grade 3 and 4) hyperglycemia in patients enrolled in the study and in patients treated per protocol, Rate of all grade hyperglycemia in patients enrolled in the study and in patients treated per protocol, Progression free survival in patients enrolled in the study and in patients treated per protocol",
905,20-001670,,150,"Identification of patients with high circulating tumor-derived deoxyribonucleic acid (ctDNA) fractions (> 50%), Detection of treatment failure",
906,SHERO,,60,Disease-free Survival,
907,YU-FTR-ST-01,,27,"Disabilities of the Arm, Shoulder, and Hand (DASH), Lymphedema Functionality, Disability, and Health Questionnaire (Lymph-ICF), Upper Extremity Lymphedema-27 (ULL-27), Quality of Life Measure for Limb Lymphedema-Arm (LYMQOL-Arm), The New York Posture Analysis (NYPA)",
908,IBCSG 55-17,,144,Pathological complete response (pCR),
909,REG-074-2020,,120,Tumour size,
910,CSIIT-C39,,40,Progression-free Survival,
911,HCC 22-003,,24,Maximum tolerated dose (MTD),
912,CSIIT-C03,,20,Efficacy Outcome: pathologic complete responseï¼pCRï¼ rateï¼ypT0/is ypN0ï¼,
913,99mTc-ZHER2,,30,"Gamma camera-based whole-body 99mTc-ZHER2:41071 uptake value (% per organ), SPECT/CT-based 99mTc-ZHER2:41071 uptake value in tumor lesions (kcounts)/SUV, SPECT-based 99mTc-ZHER2:41071 background uptake value (kcounts)/SUV, Tumor-to-background ratio (SPECT)",
914,Woman health,,40,"Body mass index, serum prolactin concentration",
915,FAST-F-PG01,,300,"Acute toxicity, Late toxicity",
916,NRG-BR007,,1670,Time to invasive or noninvasive IBTR.,
917,CLP0008,,323,"Development and validation of tumor detection algorithms in breast cancer patients receiving neoadjuvant therapy, Number of patients with reported adverse events, Reduction in residual tumor, Report on patient reported outcomes and patient preference information",
918,2022-05093-02,,1350,Recurrence Free Survival,
919,NCCH2113,,60,Invasive disease-free survival (IDFS),
920,WO42633,,1700,Invasive Disease-free Survival (IDFS),
921,GEICAM/2018-06,,315,The incidence of neratinib discontinuations due to diarrhoea at the end of 3 cycles (1 cycle= 28 days) of neratinib treatment.,
922,Soh-Med-23-01-34,,40,Diagnosis of breast cancer,
923,UPCC 01121,,96,"Determine the efficacy of HCQ or Avelumab, alone or in combination with Palbociclib, in eradicating DTCs",
924,SA20I0060,,106,"Change from Baseline in Arms lymphedema Volume on the Perometer System at 3, 6 and 9 months., Change from Baseline in Health-related quality of life on questionnaire: The European Organization for Research and Treatment in Cancer (EORTC) Quality of Life C-30 (QLQ-C30) and breast cancer-specific module QLQ-BR23 at 3, 6, and 9 months.",
925,26272819.3.0000.0068,,90,"Continuity, Continuity, Continuity, ""Subjects Satisfaction"", ""Subjects Satisfaction"", ""Subjects Satisfaction"", Bleeding pattern, Bleeding pattern, Bleeding pattern",
926,COSMOPOLITAN,,202,Fatigue 12 weeks,
927,18-040,,120,The changes in the magnitude of CD3+ T cell infiltration in tumor microenvironment,
928,Molecular imaging of HER2,,30,"Gamma camera-based whole-body 99mTc-HE3-G3 uptake value (%), SPECT-based 99mTc-HE3-G3 uptake value in tumor lesions (counts), SPECT-based 99mTc-HE3-G3background uptake value (counts), Tumor-to-background ratio (SPECT)",
929,21-VIN-0166/SAN-0647,,70,"Maximum plasma concentration during the dosing interval at steady state (CmaxSS), Area under the plasma concentration versus time curve for one dosing interval at steady state (AUC(0-t)ss)",
930,IFG-08-2019,,108,Pathological complete response (pCR) rate,
931,OP-1250-002,,30,"Incidence of Dose Limiting Toxicities, Characterization and Incidence in Adverse Events and Serious Adverse Events, Plasma levels of OP-1250 and Palbociclib",
932,MUKDEN 06,,150,Total pathological complete response rate (tpCR) in percentage,
933,1094/2020,Treatment standard has changed,0,"Acute Radiation induced toxicity (grade 2 or higher), Acute Radiation induced toxicity (grade 2 or higher)",
934,WO42133,,221,Relative Percent Change in Ki67 Scores From Baseline to Week 2,"Adverse Event, Death, Lost to Follow-up, Physician Decision, Progressive Disease, Protocol Deviation, Withdrawal by Subject"
935,HR-BLTN-002,,256,"maximum-tolerated dose (MTD), PFS as Assessed by the Investigator",
936,110-163-F,,30,Signal-to-background ratio (SBR),
937,19-524,,350,"Cancer-related physical fatigue, Health-related Quality of Life",
938,E19059,,120,Progression Free Survival,
939,KN035-TH-HER2,,59,Objective response,
940,CTO-IUSCC-0684,,38,"Safety of ASTX727 plus talazoparib using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v 5.0, Rate of dose limiting toxicity",
941,HNCH-MBC09-BM03,,300,Time to Failure(TTF),
942,0063-17,,657,"Proportion of the patients with Objective Response Rate (i.e., CR + PR) as the Best Overall Response Rate (i.e., CR + PR) in the test arm (NDLS) compared to reference arm (Taxotere)",
943,D9673R00028,,390,Difference in HRQoL based on FACT-B questionnaire at 6 months after baseline between Cohort 1 and Cohort 2,
944,NCT20210157-AI-ROL,,15500,"Cancer Detection rate, Recall or referral rate, Positive predictive value of referrals",
945,Tele-Relax,,52,"Brief Pain Inventory (BPI), ""Fatigue Impact Scale (FIS)"", Hospital Anxiety and Depression (HAD)"" scale, European Organization for Research and Treatment of Cancer- Quality of life (EORTC QLQ-C30) questionnaire, Functional Assessment of Chronic Illness Therapy-Cognitive Function (FACT-Cog), Pittsburg Sleep Quality Index (PSQI), Tampa Kinesophobia Scale (TKS)",
946,M16-735,Strategic considerations,2,Number of Participants with Dose-limiting Toxicities (DLTs),
947,ISB 1302-103,"The study was terminated during Part 1 (dose escalation), and Part 2 (expansion) of the study was not initiated. This study was voluntarily terminated due to a business decision not to proceed with the ISB 1302 asset, and not due to any safety issue.",1,"MTD: Number of DLTs (dose limiting toxicities) during the first 28 days after the first administrations of study drug (i.e. Cycle 1) in each cohort., RP2D: Incidence and severity of AEs, AESI, and SAEs, including but not limited to laboratory values, PK and biomarkers., Anti-tumor Activity of ISB 1302 administered Q1W (Part 2)",
948,KCSG BR18-16,,90,6 months progression-free survival (PFS) rate,
949,NCC1865,,30,Objective Response Rate (ORR) of CNS,
950,20-503,,30,"Rate of enrollment, Rate of adherence to prolonged overnight fasting (POF) intervention goals, Rate of adherence to exercise intervention goals",
951,A5481126,,99,"Change in PRO as measured by EORTC-QLQ-C30 collected via smartphonebased application., Physical activities as measured by wearable device.",
952,BC-Genetics,,200,Cardiotoxicity,
953,UMMCHTNBC,,40,Blood Pressure Control,
954,BTCRC-BRE18-337,,37,"Maximum Tolerated Dose (MTD) of talazoparib in combination with gedatolisib (Phase I), Objective Response Rate (ORR) (Phase II)",
955,2019/2632,,112,Participants self-efficacy,
956,LY01005/CT-CHN-303,,188,Non-inferiority of LY01005 compared with ZOLADEXÂ®: the percentage of subjects with serum E2 maintaining at postmenopausal level (â¤30 pg/mL) from Week 4 to Week 12 after the first dose.,
957,19-09020752,Initiating a new study with revised Statistics.,0,"Number of subjects achieving Objective response rate (ORR) will be assessed., Number of Subjects achieving Progression free survival (PFS), Number of subjects achieving Overall survival(OS) will be assessed.",
958,XZP-3287-3001,,300,Investigator-assessed progression free survival (PFS),
959,160178,,22,The rate of dose-limiting toxicities during the first 4 weeks of treatment,
960,20-2338,,602,Breast cancer risk perceptions,
961,J18138,Inadequate FNA samples (low cell counts),116,"Correlation of Diagnostic Cartridge With Histopathology as Assessed by Number of Participants With Same Diagnosis From Both Cancer Detection Cartridge and Core Biopsy or Resected Lesion, Correlation of Diagnostic Cartridge With Cytopathology as Assessed by Number of Participants With Same Diagnosis From Both Cancer Detection Cartridge and Cytology of Fine Needle Aspiration (FNA)",
962,GEP,,160,PFS,
963,MRG002-004,,350,Progression Free Survival (PFS) by Independent Review Committee (IRC),
964,ACTRN1261000928213,,200,Geometric mean suppression of proliferation marker Ki67,
965,PGG-BCA2121 / MK-3475-C99,,50,Overall response rate (ORR),
966,NCC2021291,,102,The rate of patients who develop radiation-associated acute toxicity (â¥ 2 degree),
967,RC31/21/0368,,102,"Evaluate the bone impact of hormone therapy remotely, Evaluate the cardiovascular impact of hormone therapy remotely",
968,Pro2020002182,,50,"Feasibility (participant retention), Acceptability (program adherence), Internet Evaluation and Utility Questionnaire",
969,Shengjing-LJY07,,500,Agreement rates with postoperative histology,
970,CNIL-2033408,,205,Prevalence of chronic pain,
971,F2017000 (UAB 17112),,40,"Phase 1: Dose-limiting toxicity (DLT), Phase 2: Objective Response Rate",
972,BTCRC-BRE19-409,,44,Progression-Free Survival (PFS),
973,BC-Pyrotinib-NVB,,30,Progression-free survival (PFS),
974,2022-A02271-42,,150,Average direct costs of the two techniques assessed (Indocyanine Green and isotopes),
975,REG-028-2021,,200,Postoperative pain,
976,SYSUCC-016,,306,HVLT R-DR,
977,HMPL-012-SPRING-R103,,45,Progression-free survival,
978,CA209-7FL,,521,Pathological Complete response (pCR) using the definition of ypT0/is ypN0,
979,2020-0342,,106,Genetic Counseling Attendance,
980,22-5307,,15,"Clearance of ctDNA with the addition of neratinib to trastuzumab-DM1 in patients with MRD detectable by the RaDaR assay, following standard neoadjuvant therapy, surgery, and initiation of T-DM1",
981,19-396,,100,Residual Cancer Burden index in surgical resection specimen,
982,CEP0431/2018 arm 2,,195,"Clinical Improvement of signs and symptoms of vulvovaginal atrophy with intravaginal LASER, Micro Ablative Radiofrequency, and topic promestriene, Satisfaction with treatment by intravaginal LASER, Micro ablative Radiofrequency, and topic promestriene for women treated for breast cancer, with genitourinary atrophy syndrome",
983,PMD-026-1-001,,50,"Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability), Maximum tolerated dose (MTD) of PMD-026, Recommended Phase 2 Dose (RP2D) of PMD-026, Efficacy in Patients",
984,201801559A3,,310,disease-free survival,
985,2022/0226,,72,"measurement of tissue stiffness (N/m), measurement of passive muscle tone (Hz), measurement of creep of tissue, measurement of the range of shoulder joint motion",
986,MA-BC-II-035,,94,tpCRï¼ypT0/is ypN0ï¼,
987,22040,,83,"Change in participant preference for adjuvant radiation treatment, Change in surgeon preference for adjuvant radiation treatment",
988,SYSUCC-011,Difficulty accruing subjects the study accrual was closed,226,The incidence of chemotherapy related adverse reaction,
989,D0816R00025,,162,To assess the safety of olaparib in Indian subjects,
990,CAAE 42627521600005274,,248,"Changes in functional capacity and muscle strength - dynamometry assessment using handgrip strength, Changes in functional and cardiopulmonary capacity - evaluation of the 6-minute walk test, Changes cardiopulmonary capacity - evaluation of the cardiac autonomic modulation through heart rate variability., Changes in Sarcopenia - muscle strength and performance assessment using Time Up and Go Test, Changes in Sarcopenia - muscle strength and performance assessment using SARC-F questionnaire, Changes in Sarcopenia - Evaluation of the corrected arm muscle area, Changes in functional and cardiopulmonary capacity - evaluation of the 6-minute step test",
991,ZYYY-BC-001,,30,pathological complete response (pCR),
992,25IB-0023,,30,"Change in frequency of effector memory immune cells, Change in frequency of central memory immune cells, Change in frequency of regulatory immune cells, Change muscle mass, Change in hand grip strength, Change in capacity to climb stairs, Change in upper body strength, Change in lower body strength, Change in levels of inflammatory factors in the blood, Change in levels of factors called microRNAs in the blood",
993,CAAE: 82691818.0.0000.5154,,80,Evaluation the Fatigability,
994,MedOPP238,Funder decision,0,"PHASE Ib: Maximum tolerated dose (MTD) / Recommended phase II dose (RP2D) of POL6326 (balixafortide), PHASE 2: Progression free survival (PFS)",
995,CTMS 17-0037,,17,Decrease in the proliferation rate of triple negative breast cancer,
996,CMTNCMB,,150,Recurrence Score variation after neoadjuvant chemotherapy,
997,18-002,,31,defining the maximum tolerated dose (MTD),
998,919PP18,,70,"Evaluation of the effect on tumor apoptosis, Chemotherapy toxicities",
999,2020-KY-140,,516,"Progression free survival, Incidence of grade 3 hand foot syndrome (rate)",
1000,18432,,42,"Changes in aromatase inhibitor-induced symptoms and overall wellbeing in postmenopausal women on aromatase inhibitor therapy, Change in Brief Pain Inventory (BPI) pain score",
